BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut. 2005;54:237-241. [PMID: 15647188 DOI: 10.1136/gut.2004.045294] [Cited by in Crossref: 466] [Cited by in F6Publishing: 409] [Article Influence: 29.1] [Reference Citation Analysis]
Number Citing Articles
1 Glick LR, Sossenheimer PH, Ollech JE, Cohen RD, Hyman NH, Hurst RD, Rubin DT. Low-Dose Metronidazole is Associated With a Decreased Rate of Endoscopic Recurrence of Crohn's Disease After Ileal Resection: A Retrospective Cohort Study. J Crohns Colitis. 2019;13:1158-1162. [PMID: 30809655 DOI: 10.1093/ecco-jcc/jjz047] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
2 Hanauer SB, Kirsner JB. Treat the Patient or Treat the Disease? Dig Dis 2012;30:400-3. [DOI: 10.1159/000338139] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
3 Eberhardson M, Söderling JK, Neovius M, Cars T, Myrelid P, Ludvigsson JF, Askling J, Ekbom A, Olén O. Anti-TNF treatment in Crohn's disease and risk of bowel resection-a population based cohort study. Aliment Pharmacol Ther 2017;46:589-98. [DOI: 10.1111/apt.14224] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 6.0] [Reference Citation Analysis]
4 Aloi M, DʼArcangelo G, Bramuzzo M, Gasparetto M, Martinelli M, Alvisi P, Illiceto MT, Valenti S, Distante M, Pellegrino S, Gatti S, Arrigo S, Civitelli F, Martelossi S; SIGENP IBD Working Group. Effect of Early Versus Late Azathioprine Therapy in Pediatric Ulcerative Colitis. Inflamm Bowel Dis 2016;22:1647-54. [PMID: 27271489 DOI: 10.1097/MIB.0000000000000828] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 3.7] [Reference Citation Analysis]
5 Zhuang X, Tian Z, Li N, Mao R, Li X, Zhao M, Xiong S, Zeng Z, Feng R, Chen M. Gut Microbiota Profiles and Microbial-Based Therapies in Post-operative Crohn's Disease: A Systematic Review. Front Med (Lausanne) 2020;7:615858. [PMID: 33585513 DOI: 10.3389/fmed.2020.615858] [Reference Citation Analysis]
6 Narula N, Wong ECL, Aruljothy A, Dulai PS, Colombel JF, Marshall JK, Ferrante M, Reinisch W. Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial. Am J Gastroenterol 2020;115:1236-45. [PMID: 32759621 DOI: 10.14309/ajg.0000000000000617] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
7 Scholmerich J. Review article: should we treat symptoms or lesions in Crohn's disease? The case for treating symptoms. Aliment Pharmacol Ther 2006;24:33-6. [DOI: 10.1111/j.1365-2036.2006.03057.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Chatu S, Subramanian V, Saxena S, Pollok RC. The role of thiopurines in reducing the need for surgical resection in Crohn’s disease: a systematic review and meta-analysis. Am J Gastroenterol. 2014;109:23-34; quiz 35. [PMID: 24322839 DOI: 10.1038/ajg.2013.402] [Cited by in Crossref: 68] [Cited by in F6Publishing: 54] [Article Influence: 8.5] [Reference Citation Analysis]
9 Lichtenstein GR, Olson A, Travers S, Diamond RH, Chen DM, Pritchard ML, Feagan BG, Cohen RD, Salzberg BA, Hanauer SB. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn’s disease. Am J Gastroenterol. 2006;101:1030-1038. [PMID: 16606351 DOI: 10.1111/j.1572-0241.2006.00463.x] [Cited by in Crossref: 139] [Cited by in F6Publishing: 120] [Article Influence: 9.3] [Reference Citation Analysis]
10 Theis VS, Rhodes JM. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther. 2008;27:19-30. [PMID: 17944997 DOI: 10.1111/j.1365-2036.2007.03553.x] [Cited by in Crossref: 69] [Cited by in F6Publishing: 61] [Article Influence: 4.9] [Reference Citation Analysis]
11 Treton X, Stefanescu C, Attar A, Alves A, Zappa M, Bouhnik Y. Sténose iléale. Gastroentérologie Clinique et Biologique 2007;31:387-92. [DOI: 10.1016/s0399-8320(07)89397-3] [Cited by in Crossref: 6] [Article Influence: 0.4] [Reference Citation Analysis]
12 Rieder F, Fiocchi C. Intestinal fibrosis in inflammatory bowel disease - Current knowledge and future perspectives. J Crohns Colitis. 2008;2:279-290. [PMID: 21172225 DOI: 10.1097/mog.0b013e3282ff8b36] [Cited by in Crossref: 36] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
13 Devlin SM, Panaccione R. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. Gastroenterol Clin North Am. 2009;38:577-594. [PMID: 19913203 DOI: 10.1016/j.gtc.2009.07.007] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
14 Cosnes J, Seksik P. Maladies inflammatoires chroniques de l’intestin : de la sulfasalazine aux biothérapies. Gastroentérologie Clinique et Biologique 2009;33:692-701. [DOI: 10.1016/j.gcb.2009.07.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
15 Schreiber S. Certolizumab pegol for the treatment of Crohn's disease. Therap Adv Gastroenterol 2011;4:375-89. [PMID: 22043230 DOI: 10.1177/1756283X11413315] [Cited by in Crossref: 35] [Cited by in F6Publishing: 19] [Article Influence: 3.5] [Reference Citation Analysis]
16 Osterman MT. Mucosal healing in inflammatory bowel disease. J Clin Gastroenterol. 2013;47:212-221. [PMID: 23340060 DOI: 10.1097/mcg.0b013e3182732ff5] [Cited by in Crossref: 37] [Cited by in F6Publishing: 13] [Article Influence: 4.6] [Reference Citation Analysis]
17 Tøttrup A, Erichsen R, Sværke C, Laurberg S, Srensen HT. Thirty-day mortality after elective and emergency total colectomy in Danish patients with inflammatory bowel disease: a population-based nationwide cohort study. BMJ Open 2012;2:e000823. [PMID: 22492386 DOI: 10.1136/bmjopen-2012-000823] [Cited by in Crossref: 59] [Cited by in F6Publishing: 54] [Article Influence: 6.6] [Reference Citation Analysis]
18 Ananthakrishnan AN, McGinley EL. Weekend hospitalisations and post-operative complications following urgent surgery for ulcerative colitis and Crohn's disease. Aliment Pharmacol Ther 2013;37:895-904. [PMID: 23451882 DOI: 10.1111/apt.12272] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
19 Battat R, Sandborn WJ. Advances in the Comprehensive Management of Postoperative Crohn's Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)00383-9. [PMID: 33819666 DOI: 10.1016/j.cgh.2021.03.048] [Reference Citation Analysis]
20 Hansen LF, Jakobsen C, Paerregaard A, Qvist N, Wewer V. Surgery and postoperative recurrence in children with Crohn disease. J Pediatr Gastroenterol Nutr 2015;60:347-51. [PMID: 25373863 DOI: 10.1097/MPG.0000000000000616] [Cited by in Crossref: 24] [Cited by in F6Publishing: 4] [Article Influence: 4.8] [Reference Citation Analysis]
21 Nguyen GC, Harris ML, Dassopoulos T. Insights in immunomodulatory therapies for ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep. 2006;8:499-505. [PMID: 17105689 DOI: 10.1007/s11894-006-0040-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
22 Tekkis PP, Nicholls RJ. Early or late surgery for patients with ileocecal Crohn's disease? Nat Rev Gastroenterol Hepatol 2008;5:304-5. [DOI: 10.1038/ncpgasthep1143] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
23 Ooi CJ, Makharia GK, Hilmi I, Gibson PR, Fock KM, Ahuja V, Ling KL, Lim WC, Thia KT, Wei SC, Leung WK, Koh PK, Gearry RB, Goh KL, Ouyang Q, Sollano J, Manatsathit S, de Silva HJ, Rerknimitr R, Pisespongsa P, Abu Hassan MR, Sung J, Hibi T, Boey CC, Moran N, Leong RW; Asia Pacific Association of Gastroenterology (APAGE) Working Group on Inflammatory Bowel Disease. Asia-Pacific consensus statements on Crohn's disease. Part 2: Management. J Gastroenterol Hepatol. 2016;31:56-68. [PMID: 25819311 DOI: 10.1111/jgh.12958] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
24 El-hussuna A, Krag A, Olaison G, Bendtsen F, Gluud LL. The Effect of Anti-Tumor Necrosis Factor Alpha Agents on Postoperative Anastomotic Complications in Crohn’s Disease: a Systematic Review. Diseases of the Colon & Rectum 2013;56:1423-33. [DOI: 10.1097/dcr.0b013e3182a48505] [Cited by in Crossref: 55] [Cited by in F6Publishing: 15] [Article Influence: 6.9] [Reference Citation Analysis]
25 Rahier JF. Prevention and management of infectious complications in IBD. Dig Dis. 2012;30:408-414. [PMID: 22796807 DOI: 10.1159/000338143] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
26 Walters TD, Hyams JS. Can early anti-TNF-α treatment be an effective therapeutic strategy in children with Crohn's disease? Immunotherapy 2014;6:799-802. [PMID: 25290411 DOI: 10.2217/imt.14.57] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
27 Fichera A, Schlottmann F, Krane M, Bernier G, Lange E. Role of surgery in the management of Crohn's disease. Current Problems in Surgery 2018;55:162-87. [DOI: 10.1067/j.cpsurg.2018.05.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
28 Brest P, Corcelle EA, Cesaro A, Chargui A, Belaïd A, Klionsky DJ, Vouret-Craviari V, Hebuterne X, Hofman P, Mograbi B. Autophagy and Crohn’s disease: at the crossroads of infection, inflammation, immunity, and cancer. Curr Mol Med. 2010;10:486-502. [PMID: 20540703 DOI: 10.2174/156652410791608252] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 4.5] [Reference Citation Analysis]
29 Matsumoto T, Iida M, Motoya S, Haruma K, Suzuki Y, Kobayashi K, Ito H, Miyata M, Kusunoki M, Chiba T, Yamamoto S, Hibi T. Therapeutic Efficacy of Infliximab on Patients with Short Duration of Crohn's Disease: A Japanese Multicenter Survey. Diseases of the Colon & Rectum 2008;51:916-23. [DOI: 10.1007/s10350-008-9241-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
30 Bourreille A, Jarry M, D'Halluin PN, Ben-Soussan E, Maunoury V, Bulois P, Sacher-Huvelin S, Vahedy K, Lerebours E, Heresbach D, Bretagne JF, Colombel JF, Galmiche JP. Wireless capsule endoscopy versus ileocolonoscopy for the diagnosis of postoperative recurrence of Crohn's disease: a prospective study. Gut. 2006;55:978-983. [PMID: 16401689 DOI: 10.1136/gut.2005.081851] [Cited by in Crossref: 155] [Cited by in F6Publishing: 123] [Article Influence: 10.3] [Reference Citation Analysis]
31 Jakobsen C, Munkholm P, Paerregaard A, Wewer V. Steroid dependency and pediatric inflammatory bowel disease in the era of immunomodulators—A population-based study: . Inflammatory Bowel Diseases 2011;17:1731-40. [DOI: 10.1002/ibd.21559] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.5] [Reference Citation Analysis]
32 Scott FI, Mamtani R, Brensinger CM, Haynes K, Chiesa-Fuxench ZC, Zhang J, Chen L, Xie F, Yun H, Osterman MT, Beukelman T, Margolis DJ, Curtis JR, Lewis JD. Risk of Nonmelanoma Skin Cancer Associated With the Use of Immunosuppressant and Biologic Agents in Patients With a History of Autoimmune Disease and Nonmelanoma Skin Cancer. JAMA Dermatol 2016;152:164-72. [PMID: 26510126 DOI: 10.1001/jamadermatol.2015.3029] [Cited by in Crossref: 82] [Cited by in F6Publishing: 53] [Article Influence: 16.4] [Reference Citation Analysis]
33 Ananthakrishnan AN. Personalizing therapy for inflammatory bowel diseases. Expert Rev Gastroenterol Hepatol 2013;7:549-58. [PMID: 23985004 DOI: 10.1586/17474124.2013.824693] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
34 Shale MJ. The implications of anti-tumour necrosis factor therapy for viral infection in patients with inflammatory bowel disease. Br Med Bull. 2009;92:61-77. [PMID: 19855102 DOI: 10.1093/bmb/ldp036] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
35 Golovics PA, Mandel MD, Lovasz BD, Lakatos PL. Inflammatory bowel disease course in Crohn’s disease: is the natural history changing? World J Gastroenterol. 2014;20:3198-3207. [PMID: 24696605 DOI: 10.3748/wjg.v20.i12.3198] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
36 Yang SB, Du SW, Wang JH. Correlation between age of onset and gastrointestinal stenosis in hospitalized patients with Crohn's disease. World J Clin Cases 2020;8:2769-77. [PMID: 32742987 DOI: 10.12998/wjcc.v8.i13.2769] [Reference Citation Analysis]
37 Montesinos MC, Desai A, Cronstein BN. Suppression of inflammation by low-dose methotrexate is mediated by adenosine A2A receptor but not A3 receptor activation in thioglycollate-induced peritonitis. Arthritis Res Ther 2006;8:R53. [PMID: 16519795 DOI: 10.1186/ar1914] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 3.7] [Reference Citation Analysis]
38 Botti F, Caprioli F, Pettinari D, Carrara A, Magarotto A, Contessini Avesani E. Surgery and diagnostic imaging in abdominal Crohn's disease. J Ultrasound 2015;18:3-17. [PMID: 25767635 DOI: 10.1007/s40477-013-0037-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
39 Frizelle FA, Ing A, Gearry RB, Whitehead M, Faragher IG, Dobbs B. Immunomodulation does not alter histology in resected Crohn’s disease. Tech Coloproctol. 2009;13:295-300. [PMID: 19774438 DOI: 10.1007/s10151-009-0538-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
40 Rieder F, Zimmermann EM, Remzi FH, Sandborn WJ. Crohn's disease complicated by strictures: a systematic review. Gut. 2013;62:1072-1084. [PMID: 23626373 DOI: 10.1136/gutjnl-2012-304353] [Cited by in Crossref: 243] [Cited by in F6Publishing: 202] [Article Influence: 30.4] [Reference Citation Analysis]
41 Thomson AB, Gupta M, Freeman HJ. Use of the tumor necrosis factor-blockers for Crohn’s disease. World J Gastroenterol. 2012;18:4823-4854. [PMID: 23002356 DOI: 10.3748/wjg.v18.i35.4823] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
42 Herfarth H. Are we ready for top-down therapy for inflammatory bowel diseases: con. Expert Review of Gastroenterology & Hepatology 2014;1:249-55. [DOI: 10.1586/17474124.1.2.249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
43 Pedersen M, Cromwell J, Nau P. Sarcopenia is a Predictor of Surgical Morbidity in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23:1867-1872. [PMID: 28604415 DOI: 10.1097/mib.0000000000001166] [Cited by in Crossref: 39] [Cited by in F6Publishing: 17] [Article Influence: 13.0] [Reference Citation Analysis]
44 Udholm LS, Rasmussen SL, Madsbøll TK, Omairi M, El-Hussuna A. A systemic review and metaanalysis of postoperative outcomes in urgent and elective bowel resection in patients with Crohn's disease. Int J Colorectal Dis 2021;36:253-63. [PMID: 33048241 DOI: 10.1007/s00384-020-03786-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Yamamoto T, Watanabe T. Strategies for the prevention of postoperative recurrence of Crohn's disease. Colorectal Dis. 2013;15:1471-1480. [PMID: 23809911 DOI: 10.1111/codi.12326] [Cited by in Crossref: 29] [Cited by in F6Publishing: 18] [Article Influence: 4.1] [Reference Citation Analysis]
46 Abou Khalil M, Abou-khalil J, Motter J, Vasilevsky C, Morin N, Ghitulescu G, Boutros M. Immunosuppressed Patients with Crohn’s Disease Are at Increased Risk of Postoperative Complications: Results from the ACS-NSQIP Database. J Gastrointest Surg 2019;23:1188-97. [DOI: 10.1007/s11605-019-04186-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Burke JP, Ferrante M, Dejaegher K, Watson RW, Docherty NG, De Hertogh G, Vermeire S, Rutgeerts P, D'Hoore A, Penninckx F, Geboes K, Van Assche G, O'Connell PR. Transcriptomic analysis of intestinal fibrosis-associated gene expression in response to medical therapy in Crohn's disease. Inflamm Bowel Dis 2008;14:1197-204. [PMID: 18452219 DOI: 10.1002/ibd.20482] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.1] [Reference Citation Analysis]
48 Danese S, Bonovas S, Lopez A, Fiorino G, Sandborn WJ, Rubin DT, Kamm MA, Colombel JF, Sands BE, Vermeire S, Panes J, Rogler G, D'Haens G, Peyrin-Biroulet L. Identification of Endpoints for Development of Antifibrosis Drugs for Treatment of Crohn's Disease. Gastroenterology 2018;155:76-87. [PMID: 29601825 DOI: 10.1053/j.gastro.2018.03.032] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
49 Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev. 2008;CD006893. [PMID: 18254120 DOI: 10.1002/14651858.cd006893] [Cited by in Crossref: 70] [Cited by in F6Publishing: 65] [Article Influence: 5.4] [Reference Citation Analysis]
50 Di Nardo G, Oliva S, Passariello M, Pallotta N, Civitelli F, Frediani S, Gualdi G, Gandullia P, Mallardo S, Cucchiara S. Intralesional steroid injection after endoscopic balloon dilation in pediatric Crohn's disease with stricture: a prospective, randomized, double-blind, controlled trial. Gastrointest Endosc. 2010;72:1201-1208. [PMID: 20951986 DOI: 10.1016/j.gie.2010.08.003] [Cited by in Crossref: 72] [Cited by in F6Publishing: 57] [Article Influence: 6.5] [Reference Citation Analysis]
51 Wolford DD, Fichera A. Prophylaxis of Crohn's disease recurrence: A surgeon's perspective. Ann Gastroenterol Surg 2020;4:514-20. [PMID: 33005846 DOI: 10.1002/ags3.12368] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
52 Pallotta N, Barberani F, Hassan NA, Guagnozzi D, Vincoli G, Corazziari E. Effect of infliximab on small bowel stenoses in patients with Crohn's disease. World J Gastroenterol 2008;14:1885-90. [PMID: 18350627 DOI: 10.3748/wjg.14.1885] [Cited by in CrossRef: 48] [Cited by in F6Publishing: 39] [Article Influence: 3.7] [Reference Citation Analysis]
53 Zidar N, Boštjančič E, Jerala M, Kojc N, Drobne D, Štabuc B, Glavač D. Down-regulation of microRNAs of the miR-200 family and up-regulation of Snail and Slug in inflammatory bowel diseases - hallmark of epithelial-mesenchymal transition. J Cell Mol Med 2016;20:1813-20. [PMID: 27113480 DOI: 10.1111/jcmm.12869] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 7.2] [Reference Citation Analysis]
54 Regueiro M. Management and prevention of postoperative Crohn's disease. Inflamm Bowel Dis 2009;15:1583-90. [PMID: 19322907 DOI: 10.1002/ibd.20909] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
55 Crowell KT, Messaris E. Risk factors and implications of anastomotic complications after surgery for Crohn's disease. World J Gastrointest Surg 2015;7:237-42. [PMID: 26523211 DOI: 10.4240/wjgs.v7.i10.237] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
56 Mao R, Gao X, Zhu ZH, Feng ST, Chen BL, He Y, Cui Y, Li ZP, Hu PJ, Chen MH. CT enterography in evaluating postoperative recurrence of Crohn's disease after ileocolic resection: complementary role to endoscopy. Inflamm Bowel Dis 2013;19:977-82. [PMID: 23511036 DOI: 10.1097/MIB.0b013e318280758c] [Cited by in Crossref: 26] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
57 Bettenworth D, Gustavsson A, Atreja A, Lopez R, Tysk C, van Assche G, Rieder F. A Pooled Analysis of Efficacy, Safety, and Long-term Outcome of Endoscopic Balloon Dilation Therapy for Patients with Stricturing Crohnʼs Disease: . Inflammatory Bowel Diseases 2017;23:133-42. [DOI: 10.1097/mib.0000000000000988] [Cited by in Crossref: 91] [Cited by in F6Publishing: 31] [Article Influence: 22.8] [Reference Citation Analysis]
58 Hausmann J, Schmelz R, Walldorf J, Filmann N, Zeuzem S, Albert JG. Pan-intestinal capsule endoscopy in patients with postoperative Crohn's disease: a pilot study. Scand J Gastroenterol. 2017;52:840-845. [PMID: 28431493 DOI: 10.1080/00365521.2017.1310289] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
59 Braus NA, Elliott DE. Advances in the pathogenesis and treatment of IBD. Clin Immunol. 2009;132:1-9. [PMID: 19321388 DOI: 10.1016/j.clim.2009.02.006] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 5.2] [Reference Citation Analysis]
60 Hovde Ø, Moum BA. Epidemiology and clinical course of Crohn’s disease: results from observational studies. World J Gastroenterol. 2012;18:1723-1731. [PMID: 22553396 DOI: 10.3748/wjg.v18.i15.1723] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 56] [Article Influence: 8.3] [Reference Citation Analysis]
61 Allocca M, Landi R, Bonovas S, Fiorino G, Papa A, Spinelli A, Furfaro F, Peyrin-Biroulet L, Armuzzi A, Danese S. Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting. Digestion 2017;96:166-72. [PMID: 28903094 DOI: 10.1159/000480231] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
62 Boal Carvalho P, Rosa B, Dias de Castro F, Moreira MJ, Cotter J. PillCam COLON 2 in Crohn's disease: A new concept of pan-enteric mucosal healing assessment. World J Gastroenterol 2015;21:7233-41. [PMID: 26109810 DOI: 10.3748/wjg.v21.i23.7233] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 35] [Article Influence: 6.6] [Reference Citation Analysis]
63 Leung Y, Geddes M, Storek J, Panaccione R, Beck PL. Hematopoietic cell transplantation for Crohn's disease; is it time? World J Gastroenterol 2006;12:6665-73. [PMID: 17075981 DOI: 10.3748/wjg.v12.i41.6665] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
64 Panaccione R, Hibi T, Peyrin-Biroulet L, Schreiber S. Implementing changes in clinical practice to improve the management of Crohn’s disease. J Crohns Colitis. 2012;6 Suppl 2:S235-S242. [PMID: 22463930 DOI: 10.1016/s1873-9946(12)60503-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
65 Jess T, Riis L, Vind I, Winther KV, Borg S, Binder V, Langholz E, Thomsen OS, Munkholm P. Changes in Clinical Characteristics, Course, and Prognosis of Inflammatory Bowel Disease during the Last 5 Decades: A Population-Based Study from Copenhagen, Denmark: . Inflammatory Bowel Diseases 2007;13:481-9. [DOI: 10.1002/ibd.20036] [Cited by in Crossref: 269] [Cited by in F6Publishing: 241] [Article Influence: 19.2] [Reference Citation Analysis]
66 Burisch J, Jess T, Martinato M, Lakatos PL; ECCO -EpiCom. The burden of inflammatory bowel disease in Europe. J Crohns Colitis. 2013;7:322-337. [PMID: 23395397 DOI: 10.1016/j.crohns.2013.01.010] [Cited by in Crossref: 541] [Cited by in F6Publishing: 447] [Article Influence: 67.6] [Reference Citation Analysis]
67 Melchior C, Loeuillard E, Marion-Letellier R, Nicol L, Mulder P, Guerin C, Bôle-Feysot C, Aziz M, Déchelotte P, Vera P, Savoye G, Savoye-Collet C. Magnetic resonance colonography for fibrosis assessment in rats with chronic colitis. PLoS One 2014;9:e100921. [PMID: 25000184 DOI: 10.1371/journal.pone.0100921] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
68 Hammoudi N, Auzolle C, Tran Minh M, Boschetti G, Bezault M, Buisson A, Pariente B, Treton X, Seksik P, Fumery M, Le Bourhis L, Nancey S, Allez M. Postoperative Endoscopic Recurrence on the Neoterminal Ileum But Not on the Anastomosis Is Mainly Driving Long-Term Outcomes in Crohn's Disease. Am J Gastroenterol 2020;115:1084-93. [DOI: 10.14309/ajg.0000000000000638] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
69 Weder B, Mamie C, Rogler G, Clarke S, McRae B, Ruiz PA, Hausmann M. BCL2 Regulates Differentiation of Intestinal Fibroblasts. Inflamm Bowel Dis 2018;24:1953-66. [PMID: 29796658 DOI: 10.1093/ibd/izy147] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
70 Siegel CA, Siegel LS, Hyams JS, Kugathasan S, Markowitz J, Rosh JR, Leleiko N, Mack DR, Crandall W, Evans J, Keljo DJ, Otley AR, Oliva-Hemker M, Farrior S, Langton CR, Wrobel IT, Wahbeh G, Quiros JA, Silber G, Bahar RJ, Sands BE, Dubinsky MC. Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. Inflamm Bowel Dis 2011;17:30-8. [PMID: 20812335 DOI: 10.1002/ibd.21386] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 4.9] [Reference Citation Analysis]
71 Kulaylat AN, Kulaylat AS, Schaefer EW, Mirkin K, Tinsley A, Williams E, Koltun WA, Hollenbeak CS, Messaris E. The Impact of Preoperative Anti-TNFα Therapy on Postoperative Outcomes Following Ileocolectomy in Crohn’s Disease. J Gastrointest Surg 2021;25:467-74. [DOI: 10.1007/s11605-019-04334-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
72 White EC, Melmed GY, Vasiliauskas E, Dubinsky M, Ippoliti A, McGovern D, Targan S, Fleshner P. Does preoperative immunosuppression influence unplanned hospital readmission after surgery in patients with Crohn's disease? Dis Colon Rectum 2012;55:563-8. [PMID: 22513435 DOI: 10.1097/DCR.0b013e3182468961] [Cited by in Crossref: 15] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
73 Zheng JJ, Chu XQ, Shi XH, Zhou CL, Seng BW. Efficacy and safety of azathioprine maintenance therapy in a group of Crohn’s disease patients in China. J Dig Dis. 2008;9:84-88. [PMID: 18419641 DOI: 10.1111/j.1751-2980.2008.00327.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
74 Ghazi LJ, Patil SA, Cross RK. Sexual Dysfunction in Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2015;21:939-47. [DOI: 10.1097/mib.0000000000000260] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
75 D’amico F, Pugliese N, Peyrin-biroulet L, Danese S. Efficacy of anti-TNFα drugs in patients with stricturing Crohn’s disease. Expert Review of Gastroenterology & Hepatology 2020;14:347-53. [DOI: 10.1080/17474124.2020.1759417] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
76 Stallmach A, Hagel S, Gharbi A, Settmacher U, Hartmann M, Schmidt C, Bruns T. Medical and surgical therapy of inflammatory bowel disease in the elderly - prospects and complications. J Crohns Colitis. 2011;5:177-188. [PMID: 21575879 DOI: 10.1016/j.crohns.2011.02.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
77 Nielsen OH, Bjerrum JT, Herfarth H, Rogler G. Recent advances using immunomodulators for inflammatory bowel disease. J Clin Pharmacol. 2013;53:575-588. [PMID: 23408468 DOI: 10.1002/jcph.2] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
78 Jones J, Panaccione R. Biologic therapy in Crohn's disease: state of the art. Curr Opin Gastroenterol. 2008;24:475-481. [PMID: 18622162 DOI: 10.1097/mog.0b013e3283043596] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
79 Myrelid P, Olaison G, Sjödahl R, Nyström PO, Almer S, Andersson P. Thiopurine therapy is associated with postoperative intra-abdominal septic complications in abdominal surgery for Crohn’s disease. Dis Colon Rectum. 2009;52:1387-1394. [PMID: 19617749 DOI: 10.1007/dcr.0b013e3181a7ba96] [Cited by in Crossref: 71] [Cited by in F6Publishing: 20] [Article Influence: 5.9] [Reference Citation Analysis]
80 Atia O, Ledder O, Ben-moshe T, Lev-tzion R, Rachmen Y, Meyer EO, Beeri R, Renbaum P, Shamasneh I, Shteyer E, Turner D. Role of Thiopurines in Pediatric Inflammatory Bowel Diseases: A Real-Life Prospective Cohort Study. Journal of Pediatric Gastroenterology & Nutrition 2020;70:825-32. [DOI: 10.1097/mpg.0000000000002566] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
81 Moran GW, Dubeau MF, Kaplan GG, Yang H, Seow CH, Fedorak RN, Dieleman LA, Barkema HW, Ghosh S, Panaccione R. Phenotypic features of Crohn’s disease associated with failure of medical treatment. Clin Gastroenterol Hepatol. 2014;12:434-42.e1. [PMID: 23978351 DOI: 10.1016/j.cgh.2013.08.026] [Cited by in Crossref: 42] [Cited by in F6Publishing: 37] [Article Influence: 5.3] [Reference Citation Analysis]
82 Golovics PA, Lakatos PL, Dávid G, Pandur T, Erdélyi Z, Horváth Á, Mester G, Balogh M, Szipocs I, Molnár C, Komáromi E, Lovász BD, Szathmári M, Kiss LS, Lakatos L. The effect of early immunosuppressive therapy on the rate of resections performed in patients with Chron’s disease, in Veszprém county, Hungary, a population-based cohort study. Orvosi Hetilap 2012;153:541-52. [DOI: 10.1556/oh.2012.29331] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
83 Seksik P, Contou J, Cosnes A, Cosnes J. Hidradenitis Suppurativa and Crohn’s Disease. In: Jemec GBE, Revuz J, Leyden JJ, editors. Hidradenitis Suppurativa. Springer Berlin Heidelberg; 2006. pp. 50-7. [DOI: 10.1007/978-3-540-33101-8_7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
84 Yamamoto T, Spinelli A, Suzuki Y, Saad-Hossne R, Teixeira FV, de Albuquerque IC, da Silva RN, de Barcelos IF, Takeuchi K, Yamada A, Shimoyama T, da Silva Kotze LM, Sacchi M, Danese S, Kotze PG. Risk factors for complications after ileocolonic resection for Crohn's disease with a major focus on the impact of preoperative immunosuppressive and biologic therapy: A retrospective international multicentre study. United European Gastroenterol J 2016;4:784-93. [PMID: 28408996 DOI: 10.1177/2050640615600116] [Cited by in Crossref: 39] [Cited by in F6Publishing: 28] [Article Influence: 6.5] [Reference Citation Analysis]
85 González-lama Y, López-san Román A, Marín-jiménez I, Casis B, Vera I, Bermejo F, Lázaro Pérez-calle J, Taxonera C, Martínez-silva F, Menchén L, Martínez-montiel P, Calvo M, Antonio Carneros J, López P, Luis Mendoza J, María Milicua J, Huerta A, Sánchez F, Abreu L, López-palacios N, Maté J, Gisberta JP. Open-label infliximab therapy in Crohn's disease: a long-term multicenter study of efficacy, safety and predictors of response. Gastroenterología y Hepatología 2008;31:421-6. [DOI: 10.1157/13125587] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
86 Caprilli R, Angelucci E, Clemente V. Recent advances in the management of Crohn's disease. Digestive and Liver Disease 2008;40:709-16. [DOI: 10.1016/j.dld.2008.02.042] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
87 Govani SM, Stidham RW, Higgins PD. How early to take arms against a sea of troubles? The case for aggressive early therapy in Crohn's disease to prevent fibrotic intestinal strictures. J Crohns Colitis 2013;7:923-7. [PMID: 23880128 DOI: 10.1016/j.crohns.2013.06.011] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
88 Smith MA, Marinaki AM, Arenas M, Shobowale-Bakre M, Lewis CM, Ansari A, Duley J, Sanderson JD. Novel pharmacogenetic markers for treatment outcome in azathioprine-treated inflammatory bowel disease. Aliment Pharmacol Ther. 2009;30:375-384. [PMID: 19500084 DOI: 10.1111/j.1365-2036.2009.04057.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 57] [Article Influence: 5.3] [Reference Citation Analysis]
89 Kono T, Hida N, Nogami K, Iimuro M, Ohda Y, Yokoyama Y, Kamikozuru K, Tozawa K, Kawai M, Ogawa T, Hori K, Ikeuchi H, Miwa H, Nakamura S, Matsumoto T. Prospective postsurgical capsule endoscopy in patients with Crohn's disease. World J Gastrointest Endosc. 2014;6:88-98. [PMID: 24634713 DOI: 10.4253/wjge.v6.i3.88] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
90 Malmborg P, Hildebrand H. The emerging global epidemic of paediatric inflammatory bowel disease--causes and consequences. J Intern Med. 2016;279:241-258. [PMID: 26355194 DOI: 10.1111/joim.12413] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
91 Holtmann MH, Krummenauer F, Claas C, Kremeyer K, Lorenz D, Rainer O, Vogel I, Böcker U, Böhm S, Büning C. Significant differences between Crohn’s disease and ulcerative colitis regarding the impact of body mass index and initial disease activity on responsiveness to azathioprine: results from a European multicenter study in 1,176 patients. Dig Dis Sci. 2010;55:1066-1078. [PMID: 19513841 DOI: 10.1007/s10620-009-0846-9] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
92 Aratari A, Papi C, Leandro G, Viscido A, Capurso L, Caprilli R. Early versus late surgery for ileo-caecal Crohn’s disease. Aliment Pharmacol Ther. 2007;26:1303-1312. [PMID: 17848181 DOI: 10.1111/j.1365-2036.2007.03515.x] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 4.1] [Reference Citation Analysis]
93 Johnson LA, Rodansky ES, Haak AJ, Larsen SD, Neubig RR, Higgins PD. Novel Rho/MRTF/SRF inhibitors block matrix-stiffness and TGF-β-induced fibrogenesis in human colonic myofibroblasts. Inflamm Bowel Dis 2014;20:154-65. [PMID: 24280883 DOI: 10.1097/01.MIB.0000437615.98881.31] [Cited by in Crossref: 112] [Cited by in F6Publishing: 63] [Article Influence: 16.0] [Reference Citation Analysis]
94 Dillman JR, Stidham RW, Higgins PD, Moons DS, Johnson LA, Rubin JM. US elastography-derived shear wave velocity helps distinguish acutely inflamed from fibrotic bowel in a Crohn disease animal model. Radiology. 2013;267:757-766. [PMID: 23401585 DOI: 10.1148/radiol.13121775] [Cited by in Crossref: 66] [Cited by in F6Publishing: 57] [Article Influence: 8.3] [Reference Citation Analysis]
95 López-Sanromán A, Vera-Mendoza I, Domènech E, Taxonera C, Vega Ruiz V, Marín-Jiménez I, Guardiola J, Castro L, Esteve M, Iglesias E, Ceballos D, Martínez-Montiel P, Gisbert JP, Mínguez M, Echarri A, Calvet X, Barrio J, Hinojosa J, Martín-Arranz MD, Márquez-Mosquera L, Bermejo F, Rimola J, Pons V, Nos P; Spanish GETECCU group [APPRECIA study]. Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn's Disease Recurrence. A GETECCU Randomised Trial. J Crohns Colitis 2017;11:1293-301. [PMID: 28402454 DOI: 10.1093/ecco-jcc/jjx051] [Cited by in Crossref: 34] [Cited by in F6Publishing: 23] [Article Influence: 11.3] [Reference Citation Analysis]
96 Brennan GT, Melton SD, Spechler SJ, Feagins LA. Clinical implications of histologic abnormalities in ileocolonic biopsies of patients with Crohn's disease in remission. J Clin Gastroenterol. 2017;51:43-48. [PMID: 26927490 DOI: 10.1097/mcg.0000000000000507] [Cited by in Crossref: 23] [Cited by in F6Publishing: 7] [Article Influence: 5.8] [Reference Citation Analysis]
97 Golovics PA, Lakatos L, Nagy A, Pandur T, Szita I, Balogh M, Molnar C, Komaromi E, Lovasz BD, Mandel M. Is early limited surgery associated with a more benign disease course in Crohn’s disease? World J Gastroenterol. 2013;19:7701-7710. [PMID: 24282358 DOI: 10.3748/wjg.v19.i43.7701] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
98 Fumery M, Dulai PS, Meirick P, Farrell AM, Ramamoorthy S, Sandborn WJ, Singh S. Systematic review with meta-analysis: recurrence of Crohn's disease after total colectomy with permanent ileostomy. Aliment Pharmacol Ther 2017;45:381-90. [PMID: 27928830 DOI: 10.1111/apt.13886] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 3.8] [Reference Citation Analysis]
99 Abhyankar A, Ham M, Moss AC. Meta-analysis: the impact of disease activity at conception on disease activity during pregnancy in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;38:460-466. [PMID: 23855477 DOI: 10.1111/apt.12417] [Cited by in Crossref: 82] [Cited by in F6Publishing: 67] [Article Influence: 10.3] [Reference Citation Analysis]
100 Limketkai BN, Orandi BJ, Luo X, Segev DL, Colombel J. Mortality and Rates of Graft Rejection or Failure Following Intestinal Transplantation in Patients With vs Without Crohn’s Disease. Clinical Gastroenterology and Hepatology 2016;14:1574-81. [DOI: 10.1016/j.cgh.2016.06.020] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
101 Domènech E, Mañosa M, Bernal I, Garcia-planella E, Cabré E, Piñol M, Lorenzo-zúñiga V, Boix J, Gassull MA. Impact of azathioprine on the prevention of postoperative Crohnʼs disease recurrence: Results of a prospective, observational, long-term follow-up study: . Inflammatory Bowel Diseases 2008;14:508-13. [DOI: 10.1002/ibd.20359] [Cited by in Crossref: 61] [Cited by in F6Publishing: 52] [Article Influence: 4.7] [Reference Citation Analysis]
102 Cosnes J, Bourrier A, Laharie D, Nahon S, Bouhnik Y, Carbonnel F, Allez M, Dupas JL, Reimund JM, Savoye G. Early administration of azathioprine vs conventional management of Crohn’s Disease: a randomized controlled trial. Gastroenterology. 2013;145:758-765.e2; quiz e14-5. [PMID: 23644079 DOI: 10.1053/j.gastro.2013.04.048] [Cited by in Crossref: 191] [Cited by in F6Publishing: 148] [Article Influence: 23.9] [Reference Citation Analysis]
103 Burke JP, Mulsow JJ, O'Keane C, Docherty NG, Watson RW, O'Connell PR. Fibrogenesis in Crohn's disease. Am J Gastroenterol. 2007;102:439-448. [PMID: 17156147 DOI: 10.1111/j.1572-0241.2006.01010.x] [Cited by in Crossref: 189] [Cited by in F6Publishing: 184] [Article Influence: 12.6] [Reference Citation Analysis]
104 Bessissow T, Reinglas J, Aruljothy A, Lakatos PL, Van Assche G. Endoscopic management of Crohn's strictures. World J Gastroenterol. 2018;24:1859-1867. [PMID: 29740201 DOI: 10.3748/wjg.v24.i17.1859] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
105 Velayos FS, Sandborn WJ. Positioning biologic therapy for Crohn’s disease and ulcerative colitis. Curr Gastroenterol Rep 2007;9:521-7. [DOI: 10.1007/s11894-007-0069-1] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
106 Bharadwaj S, Fleshner P, Shen B. Therapeutic Armamentarium for Stricturing Crohn's Disease: Medical Versus Endoscopic Versus Surgical Approaches. Inflamm Bowel Dis 2015;21:2194-213. [PMID: 25985249 DOI: 10.1097/MIB.0000000000000403] [Cited by in Crossref: 44] [Cited by in F6Publishing: 12] [Article Influence: 8.8] [Reference Citation Analysis]
107 Kjeldsen J, Nielsen J, Larsen MD, Qvist N, Nørgård BM. Postoperative Use of Anti-TNF-α Agents in Patients with Crohnʼs Disease and Risk of Reoperation—A Nationwide Cohort Study: . Inflammatory Bowel Diseases 2016;22:599-606. [DOI: 10.1097/mib.0000000000000647] [Cited by in Crossref: 5] [Article Influence: 1.0] [Reference Citation Analysis]
108 Seksik P, Nion-Larmurier I, Sokol H, Beaugerie L, Cosnes J. Effects of light smoking consumption on the clinical course of Crohn's disease. Inflamm Bowel Dis 2009;15:734-41. [PMID: 19067428 DOI: 10.1002/ibd.20828] [Cited by in Crossref: 50] [Cited by in F6Publishing: 49] [Article Influence: 4.2] [Reference Citation Analysis]
109 Lee KM, Lee JM. Crohn's disease in Korea: past, present, and future. Korean J Intern Med 2014;29:558-70. [PMID: 25228829 DOI: 10.3904/kjim.2014.29.5.558] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 2.4] [Reference Citation Analysis]
110 Jung YS, Hong SP, Kim TI, Kim WH, Cheon JH. Early versus late surgery in patients with intestinal Behçet disease. Dis Colon Rectum. 2012;55:65-71. [PMID: 22156869 DOI: 10.1097/DCR.0b013e318238b57e] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
111 Latella G, Caprilli R, Travis S. In favour of early surgery in Crohn's disease: a hypothesis to be tested. J Crohns Colitis. 2011;5:1-4. [PMID: 21272796 DOI: 10.1016/j.crohns.2010.11.003] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
112 Meier R, Lutz C, Cosín-roger J, Fagagnini S, Bollmann G, Hünerwadel A, Mamie C, Lang S, Tchouboukov A, Weber FE, Weber A, Rogler G, Hausmann M. Decreased Fibrogenesis After Treatment with Pirfenidone in a Newly Developed Mouse Model of Intestinal Fibrosis: . Inflammatory Bowel Diseases 2016;22:569-82. [DOI: 10.1097/mib.0000000000000716] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 5.4] [Reference Citation Analysis]
113 de Bruyn JR, Meijer SL, Wildenberg ME, Bemelman WA, van den Brink GR, D'Haens GR. Development of Fibrosis in Acute and Longstanding Ulcerative Colitis. J Crohns Colitis 2015;9:966-72. [PMID: 26245217 DOI: 10.1093/ecco-jcc/jjv133] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
114 Schirbel A, Reichert A, Roll S, Baumgart DC, Büning C, Wittig B, Wiedenmann B, Dignass A, Sturm A. Impact of pain on health-related quality of life in patients with inflammatory bowel disease. World J Gastroenterol. 2010;16:3168-3177. [PMID: 20593502 DOI: 10.3748/wjg.v16.i25.3168] [Cited by in CrossRef: 76] [Cited by in F6Publishing: 65] [Article Influence: 6.9] [Reference Citation Analysis]
115 Zhang J, Wei S, Zeng Q, Wu X, Gan H. Prevalence and risk factors of sexual dysfunction in patients with inflammatory bowel disease: systematic review and meta-analysis. Int J Colorectal Dis 2021;36:2027-38. [PMID: 34050786 DOI: 10.1007/s00384-021-03958-y] [Reference Citation Analysis]
116 Goldberg R, Irving PM. Toxicity and response to thiopurines in patients with inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2015;9:891-900. [PMID: 25915575 DOI: 10.1586/17474124.2015.1039987] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
117 Pasternak B, Svanström H, Schmiegelow K, Jess T, Hviid A. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol. 2013;177:1296-1305. [PMID: 23514635 DOI: 10.1093/aje/kws375] [Cited by in Crossref: 124] [Cited by in F6Publishing: 99] [Article Influence: 15.5] [Reference Citation Analysis]
118 de Buck van Overstraeten A, Wolthuis A, D’Hoore A. Surgery for Crohn’s disease in the era of biologicals: a reduced need or delayed verdict? World J Gastroenterol. 2012;18:3828-3832. [PMID: 22876034 DOI: 10.3748/wjg.v18.i29.3828] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 26] [Article Influence: 3.9] [Reference Citation Analysis]
119 Rosen DJ, Dubinsky MC. The Evolving Role of Thiopurines for Inflammatory Bowel Disease. Inflamm Bowel Dis 2016;22:234-40. [PMID: 26355469 DOI: 10.1097/MIB.0000000000000583] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.4] [Reference Citation Analysis]
120 Lin MV, Blonski W, Lichtenstein GR. What is the optimal therapy for Crohn‘s disease: step-up or top-down? Expert Rev Gastroenterol Hepatol. 2010;4:167-180. [PMID: 20350264 DOI: 10.1586/egh.10.4] [Cited by in Crossref: 31] [Cited by in F6Publishing: 21] [Article Influence: 2.8] [Reference Citation Analysis]
121 Bernstein CN. The Natural History of Inflammatory Bowel Disease. In: Baumgart DC, editor. Crohn's Disease and Ulcerative Colitis. Boston: Springer US; 2012. pp. 343-63. [DOI: 10.1007/978-1-4614-0998-4_26] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
122 Lakatos PL, Kiss LS. Current status of thiopurine analogues in the treatment in Crohn’s disease. World J Gastroenterol. 2011;17:4372-4381. [PMID: 22110262 DOI: 10.3748/wjg.v17.i39.4372] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
123 Ansari A, Elliott T, Baburajan B, Mayhead P, O'Donohue J, Chocair P, Sanderson J, Duley J. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment Pharmacol Ther 2008;28:734-41. [PMID: 19145729 DOI: 10.1111/j.1365-2036.2008.03782.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 74] [Article Influence: 7.2] [Reference Citation Analysis]
124 Chande N, Marshall JK, Seow CH, Sandborn WJ, Parker CE, Nelson S, Feagan BG. New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us? Inflammatory Bowel Diseases 2015;21:2948-57. [DOI: 10.1097/mib.0000000000000631] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
125 Shahidi N, Fu YT, Qian H, Bressler B. Performance of interferon-gamma release assays in patients with inflammatory bowel disease: a systematic review and meta-analysis. Inflamm Bowel Dis. 2012;18:2034-2042. [PMID: 22294550 DOI: 10.1002/ibd.22901] [Cited by in Crossref: 43] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
126 Lai HC, Chang CH, Cheng KS, Chen TW, Tsai YY, Chou JW. QuantiFERON-TB Gold Test Conversion Is Associated with Active Tuberculosis Development in Inflammatory Bowel Disease Patients Treated with Biological Agents: An Experience of a Medical Center in Taiwan. Gastroenterol Res Pract 2019;2019:7132875. [PMID: 31781198 DOI: 10.1155/2019/7132875] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Blaker PA, Arenas-hernandez M, Marinaki AM, Sanderson JD. The pharmacogenetic basis of individual variation in thiopurine metabolism. Personalized Medicine 2012;9:707-25. [DOI: 10.2217/pme.12.85] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
128 Tzivanakis A, Singh JC, Guy RJ, Travis SP, Mortensen NJ, George BD. Influence of risk factors on the safety of ileocolic anastomosis in Crohn's disease surgery. Dis Colon Rectum 2012;55:558-62. [PMID: 22513434 DOI: 10.1097/DCR.0b013e318247c433] [Cited by in Crossref: 63] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
129 Mao R, Kurada S, Gordon IO, Baker ME, Gandhi N, McDonald C, Coffey JC, Rieder F. The Mesenteric Fat and Intestinal Muscle Interface: Creeping Fat Influencing Stricture Formation in Crohn's Disease. Inflamm Bowel Dis. 2019;25:421-426. [PMID: 30346528 DOI: 10.1093/ibd/izy331] [Cited by in Crossref: 39] [Cited by in F6Publishing: 31] [Article Influence: 39.0] [Reference Citation Analysis]
130 Lindsay J, Punekar YS, Morris J, Chung-Faye G. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease--modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther. 2008;28:76-87. [PMID: 18410558 DOI: 10.1111/j.1365-2036.2008.03709.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 53] [Article Influence: 4.8] [Reference Citation Analysis]
131 Baert F, Caprilli R, Angelucci E. Medical therapy for Crohn's disease: top-down or step-up? Dig Dis. 2007;25:260-266. [PMID: 17827952 DOI: 10.1159/000103897] [Cited by in Crossref: 27] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
132 Bettenworth D, Nowacki TM, Cordes F, Buerke B, Lenze F. Assessment of stricturing Crohn's disease: Current clinical practice and future avenues. World J Gastroenterol. 2016;22:1008-1016. [PMID: 26811643 DOI: 10.3748/wjg.v22.i3.1008] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
133 Chouchana L, Narjoz C, Beaune P, Loriot M, Roblin X. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease: Review: pharmacogenetics of thiopurines in IBD. Alimentary Pharmacology & Therapeutics 2012;35:15-36. [DOI: 10.1111/j.1365-2036.2011.04905.x] [Cited by in Crossref: 111] [Cited by in F6Publishing: 93] [Article Influence: 11.1] [Reference Citation Analysis]
134 Greenberg R, Greenwald B, Roth JS, Ioffe O, Cross R. Squamous dysplasia of the rectum in a patient with ulcerative colitis treated with 6-mercaptopurine. Dig Dis Sci. 2008;53:760-764. [PMID: 17717741 DOI: 10.1007/s10620-007-9935-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
135 Latella G, Papi C. Crucial steps in the natural history of inflammatory bowel disease. World J Gastroenterol. 2012;18:3790-3799. [PMID: 22876029 DOI: 10.3748/wjg.v18.i29.3790] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 58] [Article Influence: 8.8] [Reference Citation Analysis]
136 Park SH, Yang SK, Park SK, Kim JW, Yang DH, Jung KW, Kim KJ, Ye BD, Byeon JS, Myung SJ, Yoon YS, Yu CS, Kim JH. Long-term prognosis of crohn's disease and its temporal change between 1981 and 2012: a hospital-based cohort study from Korea. Inflamm Bowel Dis. 2014;20:488-494. [PMID: 24412992 DOI: 10.1097/01.mib.0000441203.56196.46] [Cited by in Crossref: 75] [Cited by in F6Publishing: 36] [Article Influence: 10.7] [Reference Citation Analysis]
137 Rajca S, Seksik P, Bourrier A, Sokol H, Nion-Larmurier I, Beaugerie L, Cosnes J. Impact of the diagnosis and treatment of cancer on the course of inflammatory bowel disease. J Crohns Colitis. 2014;8:819-824. [PMID: 24439392 DOI: 10.1016/j.crohns.2013.12.022] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
138 Ghosh S, Panaccione R. Anti-adhesion molecule therapy for inflammatory bowel disease. Therap Adv Gastroenterol. 2010;3:239-258. [PMID: 21180606 DOI: 10.1177/1756283x10373176] [Cited by in Crossref: 76] [Cited by in F6Publishing: 26] [Article Influence: 7.6] [Reference Citation Analysis]
139 Zidar N, Langner C, Jerala M, Boštjančič E, Drobne D, Tomažič A. Pathology of Fibrosis in Crohn's Disease-Contribution to Understanding Its Pathogenesis. Front Med (Lausanne) 2020;7:167. [PMID: 32432120 DOI: 10.3389/fmed.2020.00167] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
140 Lee CK, Kim HS, Ye BD, Lee KM, Kim YS, Rhee SY, Kim HJ, Yang SK, Moon W, Koo JS, Lee SH, Seo GS, Park SJ, Choi CH, Jung SA, Hong SN, Im JP, Kim ES; Korean Association for the Study of Intestinal Diseases (KASID) Study. Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine. J Crohns Colitis 2014;8:384-91. [PMID: 24144611 DOI: 10.1016/j.crohns.2013.09.022] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 4.0] [Reference Citation Analysis]
141 Pandey A, Salazar E, Kong CSC, Lim WC, Ong J, Ong DEH, Ong C, Aw M, Wee E, Chuah SW, Tan V, Tay WL, Nadkarni N, Ling KL. Risk of Major Abdominal Surgery in an Asian Population-based Crohnʼs Disease Cohort: . Inflammatory Bowel Diseases 2015;21:2625-33. [DOI: 10.1097/mib.0000000000000525] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
142 Regueiro M, Kip KE, Schraut W, Baidoo L, Sepulveda AR, Pesci M, El-Hachem S, Harrison J, Binion D. Crohn’s disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection. Inflamm Bowel Dis. 2011;17:118-126. [PMID: 20848538 DOI: 10.1002/ibd.21355] [Cited by in Crossref: 96] [Cited by in F6Publishing: 78] [Article Influence: 9.6] [Reference Citation Analysis]
143 Huang ML, Ran ZH, Shen J, Li XB, Xu XT, Xiao SD. Efficacy and safety of adalimumab in Crohn's disease: Meta-analysis of placebo-controlled trials: Adalimumab in Crohn's disease. Journal of Digestive Diseases 2011;12:165-72. [DOI: 10.1111/j.1751-2980.2011.00493.x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
144 Limketkai BN, Bayless TM. Editorial: Can stenosis in ileal Crohn's disease be prevented by current therapy? Am J Gastroenterol 2013;108:1755-6. [PMID: 24192948 DOI: 10.1038/ajg.2013.301] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
145 Rieder F, Kugathasan S. Circulating antibodies against bacterial wall products: are there arguments for early immunosuppression? Dig Dis. 2012;30 Suppl 3:55-66. [PMID: 23295693 DOI: 10.1159/000342603] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
146 De Cruz P, Kamm MA, Prideaux L, Allen PB, Moore G. Mucosal Healing in Crohnʼs Disease: A Systematic Review. Inflammatory Bowel Diseases 2013;19:429-44. [DOI: 10.1002/ibd.22977] [Cited by in Crossref: 101] [Cited by in F6Publishing: 86] [Article Influence: 12.6] [Reference Citation Analysis]
147 Aloi M, Viola F, D'Arcangelo G, Di Nardo G, Civitelli F, Casciani E, Oliva S, Nuti F, Dilillo A, Cucchiara S. Disease course and efficacy of medical therapy in stricturing paediatric Crohn's disease. Dig Liver Dis 2013;45:464-8. [PMID: 23465684 DOI: 10.1016/j.dld.2013.01.020] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
148 Gu YB, Zhong J;  Chinese IBD Endoscopic Club. Endoscopic management of stricturing Crohn's disease. J Dig Dis. 2020;21:351-354. [PMID: 32537911 DOI: 10.1111/1751-2980.12914] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
149 Sokol H, Brot L, Stefanescu C, Auzolle C, Barnich N, Buisson A, Fumery M, Pariente B, Le Bourhis L, Treton X, Nancey S, Allez M, Seksik P; REMIND Study Group Investigators. Prominence of ileal mucosa-associated microbiota to predict postoperative endoscopic recurrence in Crohn's disease. Gut. 2020;69:462-472. [PMID: 31142586 DOI: 10.1136/gutjnl-2019-318719] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 13.5] [Reference Citation Analysis]
150 Yun SM, Kim SH, Kim EH. The Molecular Mechanism of Transforming Growth Factor-β Signaling for Intestinal Fibrosis: A Mini-Review. Front Pharmacol 2019;10:162. [PMID: 30873033 DOI: 10.3389/fphar.2019.00162] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 11.0] [Reference Citation Analysis]
151 Jones GR, Kennedy NA, Lees CW, Arnott ID, Satsangi J. Systematic review: The use of thiopurines or anti-TNF in post-operative Crohn’s disease maintenance--progress and prospects. Aliment Pharmacol Ther. 2014;39:1253-1265. [PMID: 24738574 DOI: 10.1111/apt.12743] [Cited by in Crossref: 36] [Cited by in F6Publishing: 25] [Article Influence: 5.1] [Reference Citation Analysis]
152 Schoenfeld PS, Loftus EV. Evidence-Based Medicine (EBM) in Practice: Understanding Tests of Heterogeneity in Metaanalysis. Am J Gastroenterology 2005;100:1221-3. [DOI: 10.1111/j.1572-0241.2005.50452.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
153 Nguyen DL, Solaimani P, Nguyen ET, Jamal MM, Bechtold ML. Antitumor necrosis factor α is more effective than conventional medical therapy for the prevention of postoperative recurrence of Crohn’s disease: a meta-analysis. European Journal of Gastroenterology & Hepatology 2014;26:1152-9. [DOI: 10.1097/meg.0000000000000178] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 1.9] [Reference Citation Analysis]
154 Swoger JM, Regueiro M. Evaluation for postoperative recurrence of Crohn disease. Gastroenterol Clin North Am. 2012;41:303-314. [PMID: 22500519 DOI: 10.1016/j.gtc.2012.01.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
155 Peyrin-Biroulet L, Cadranel JF, Nousbaum JB, Oussalah A, Seddik M, Canva V, Cortot A, Sogni P, Gueant JL, Bigard MA, Roblin X, Bronowicki JP. Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression. Aliment Pharmacol Ther 2008;28:984-93. [PMID: 18657132 DOI: 10.1111/j.1365-2036.2008.03812.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
156 Palacio FGM, de Souza LMP, Moreira JPL, Luiz RR, de Souza HSP, Zaltman C. Hospitalization and surgery rates in patients with inflammatory bowel disease in Brazil: a time-trend analysis. BMC Gastroenterol 2021;21:192. [PMID: 33906627 DOI: 10.1186/s12876-021-01781-x] [Reference Citation Analysis]
157 An V, Cohen L, Lawrence M, Thomas M, Andrews J, Moore J. Early surgery in Crohn's disease a benefit in selected cases. World J Gastrointest Surg 2016;8:492-500. [PMID: 27462391 DOI: 10.4240/wjgs.v8.i7.492] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.8] [Reference Citation Analysis]
158 Lazarev M, Ullman T, Schraut WH, Kip KE, Saul M, Regueiro M. Small bowel resection rates in Crohn’s disease and the indication for surgery over time: experience from a large tertiary care center. Inflamm Bowel Dis. 2010;16:830-835. [PMID: 19798731 DOI: 10.1002/ibd.21118] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 5.8] [Reference Citation Analysis]
159 El-hussuna A, Andersen J, Bisgaard T, Jess P, Henriksen M, Oehlenschlager J, Thorlacius-ussing O, Olaison G. Biologic treatment or immunomodulation is not associated with postoperative anastomotic complications in abdominal surgery for Crohn's disease. Scandinavian Journal of Gastroenterology 2012;47:662-8. [DOI: 10.3109/00365521.2012.660540] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 6.3] [Reference Citation Analysis]
160 Galata C, Kienle P, Weiss C, Seyfried S, Reißfelder C, Hardt J. Risk factors for early postoperative complications in patients with Crohn's disease after colorectal surgery other than ileocecal resection or right hemicolectomy. Int J Colorectal Dis 2019;34:293-300. [PMID: 30460473 DOI: 10.1007/s00384-018-3196-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
161 Hashash JG, Regueiro MD. The evolving management of postoperative Crohn’s disease. Expert Rev Gastroenterol Hepatol. 2012;6:637-648. [PMID: 23061713 DOI: 10.1586/egh.12.45] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
162 Pérez-bosque A, Miró L, Maijó M, Polo J, Campbell J, Russell L, Crenshaw J, Weaver E, Moretó M. Dietary intervention with serum-derived bovine immunoglobulins protects barrier function in a mouse model of colitis. American Journal of Physiology-Gastrointestinal and Liver Physiology 2015;308:G1012-8. [DOI: 10.1152/ajpgi.00378.2014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
163 Pelletier AL, Kalisazan B, Wienckiewicz J, Bouarioua N, Soulé JC. Infliximab treatment for symptomatic Crohn’s disease strictures. Aliment Pharmacol Ther. 2009;29:279-285. [PMID: 19035967 DOI: 10.1111/j.1365-2036.2008.03887.x] [Cited by in Crossref: 59] [Cited by in F6Publishing: 45] [Article Influence: 4.5] [Reference Citation Analysis]
164 Mossop H, Davies P, Murphy MS. Predicting the need for azathioprine at first presentation in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2008;47:123-9. [PMID: 18664861 DOI: 10.1097/MPG.0b013e318156a834] [Cited by in Crossref: 13] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
165 Tavernier M, Lebreton G, Alves A. Laparoscopic surgery for complex Crohn’s disease. J Visc Surg. 2013;150:389-393. [PMID: 24119432 DOI: 10.1016/j.jviscsurg.2013.09.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
166 Salas A, Ricart E, Panés J. Cell therapies for inflammatory bowel diseases. Expert Review of Gastroenterology & Hepatology 2014;3:321-4. [DOI: 10.1586/egh.09.26] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
167 Schoepfer AM, Dehlavi MA, Fournier N, Safroneeva E, Straumann A, Pittet V, Peyrin-Biroulet L, Michetti P, Rogler G, Vavricka SR; IBD Cohort Study Group. Diagnostic delay in Crohn's disease is associated with a complicated disease course and increased operation rate. Am J Gastroenterol. 2013;108:1744-1753; quiz 1754. [PMID: 23978953 DOI: 10.1038/ajg.2013.248] [Cited by in Crossref: 117] [Cited by in F6Publishing: 95] [Article Influence: 14.6] [Reference Citation Analysis]
168 Cosnes J, Gower-Rousseau C, Seksik P, Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. 2011;140:1785-1794. [PMID: 21530745 DOI: 10.1053/j.gastro.2011.01.055] [Cited by in Crossref: 1157] [Cited by in F6Publishing: 982] [Article Influence: 115.7] [Reference Citation Analysis]
169 Landerholm K, Kalman D, Wallon C, Myrelid P. Immunomodulators: Friends or Enemies in Surgery for Crohn’s Disease? CDT 2019;20:1384-98. [DOI: 10.2174/1389450120666190617163919] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
170 Rao VL, Micic D, Kim KE. Primary Care Evaluation and Management of Gastroenterologic Issues in Women. Obstet Gynecol Clin North Am 2016;43:347-66. [PMID: 27212096 DOI: 10.1016/j.ogc.2016.01.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
171 O'Donnell S, Borowski K, Espin-Garcia O, Milgrom R, Kabakchiev B, Stempak J, Panikkath D, Eksteen B, Xu W, Steinhart AH, Kaplan GG, McGovern DPB, Silverberg MS. The Unsolved Link of Genetic Markers and Crohn's Disease Progression: A North American Cohort Experience. Inflamm Bowel Dis 2019;25:1541-9. [PMID: 30801121 DOI: 10.1093/ibd/izz016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
172 Bello C, Belaiche J, Louis E, Reenaers C. Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids. J Crohns Colitis. 2011;5:196-202. [PMID: 21575881 DOI: 10.1016/j.crohns.2010.12.011] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
173 Zhulina Y, Udumyan R, Tysk C, Montgomery S, Halfvarson J. The changing face of Crohn’s disease: a population-based study of the natural history of Crohn’s disease in Örebro, Sweden 1963–2005. Scandinavian Journal of Gastroenterology 2015;51:304-13. [DOI: 10.3109/00365521.2015.1093167] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
174 Smith M, Blaker P, Patel C, Marinaki A, Arenas M, Escuredo E, Anderson S, Irving P, Sanderson J. The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic. Int J Clin Pract. 2013;67:161-169. [PMID: 23253089 DOI: 10.1111/ijcp.12039] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 4.7] [Reference Citation Analysis]
175 Cheifetz AS. Management of active Crohn disease. JAMA 2013;309:2150-8. [PMID: 23695484 DOI: 10.1001/jama.2013.4466] [Cited by in Crossref: 72] [Cited by in F6Publishing: 52] [Article Influence: 9.0] [Reference Citation Analysis]
176 Baars JE, Siegel CA, Kuipers EJ, van der Woude CJ. Patient's perspectives important for early anti-tumor necrosis factor treatment in inflammatory bowel disease. Digestion 2009;79:30-5. [PMID: 19246918 DOI: 10.1159/000203638] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
177 Stallmach A, Hagel S, Bruns T. Adverse effects of biologics used for treating IBD. Best Pract Res Clin Gastroenterol. 2010;24:167-182. [PMID: 20227030 DOI: 10.1016/j.bpg.2010.01.002] [Cited by in Crossref: 114] [Cited by in F6Publishing: 94] [Article Influence: 10.4] [Reference Citation Analysis]
178 Peyrin-Biroulet L, Khosrotehrani K, Carrat F, Bouvier AM, Chevaux JB, Simon T, Carbonnel F, Colombel JF, Dupas JL, Godeberge P. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology. 2011;141:1621-1628.e1-5. [PMID: 21708105 DOI: 10.1053/j.gastro.2011.06.050] [Cited by in Crossref: 288] [Cited by in F6Publishing: 247] [Article Influence: 28.8] [Reference Citation Analysis]
179 Dubinsky MC, Kugathasan S, Kwon S, Haritunians T, Wrobel I, Wahbeh G, Quiros A, Bahar R, Silber G, Farrior S, Stephens M, Teleten N, Panikkath D, Ippoliti A, Vasiliauskas E, Fleshner P, Williams C, Landers C, Rotter JI, Targan SR, Taylor KD, McGovern DP. Multidimensional prognostic risk assessment identifies association between IL12B variation and surgery in Crohn's disease. Inflamm Bowel Dis 2013;19:1662-70. [PMID: 23665963 DOI: 10.1097/MIB.0b013e318281f275] [Cited by in Crossref: 31] [Cited by in F6Publishing: 12] [Article Influence: 4.4] [Reference Citation Analysis]
180 Lewis JD, Gelfand JM, Troxel AB, Forde KA, Newcomb C, Kim H, Margolis DJ, Strom BL. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol. 2008;103:1428-1435; quiz 1436. [PMID: 18494836 DOI: 10.1111/j.1572-0241.2008.01836.x] [Cited by in Crossref: 63] [Cited by in F6Publishing: 58] [Article Influence: 4.8] [Reference Citation Analysis]
181 Colombel J. Efficacy and safety of adalimumab for the treatment of Crohn’s disease in adults. Expert Review of Gastroenterology & Hepatology 2014;2:163-76. [DOI: 10.1586/17474124.2.2.163] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.7] [Reference Citation Analysis]
182 Armuzzi A, De Pascalis B, Fedeli P, De Vincentis F, Gasbarrini A. Infliximab in Crohn's disease: early and long-term treatment. Digestive and Liver Disease 2008;40:S271-9. [DOI: 10.1016/s1590-8658(08)60537-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
183 Van Gossum A, Dewit O, Louis E, de Hertogh G, Baert F, Fontaine F, Devos M, Enslen M, Paintin M, Franchimont D. Multicenter randomized-controlled clinical trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohnʼs disease after ileo-caecal resection: . Inflammatory Bowel Diseases 2007;13:135-42. [DOI: 10.1002/ibd.20063] [Cited by in Crossref: 194] [Cited by in F6Publishing: 163] [Article Influence: 13.9] [Reference Citation Analysis]
184 Chen M, Yi F, Zhou F, Huang M, Li J, Yan W, Li L, Xia B. Risk factors for initial surgery in patients with Crohn's disease in Central China. Surg Today 2015;45:1002-8. [PMID: 25524561 DOI: 10.1007/s00595-014-1093-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
185 Peyrin-Biroulet L, Deltenre P, Ardizzone S, D’Haens G, Hanauer SB, Herfarth H, Lémann M, Colombel JF. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn’s disease: a meta-analysis. Am J Gastroenterol. 2009;104:2089-2096. [PMID: 19568226 DOI: 10.1038/ajg.2009.301] [Cited by in Crossref: 167] [Cited by in F6Publishing: 136] [Article Influence: 13.9] [Reference Citation Analysis]
186 Regueiro M, Kip KE, Baidoo L, Swoger JM, Schraut W. Postoperative therapy with infliximab prevents long-term Crohn’s disease recurrence. Clin Gastroenterol Hepatol. 2014;12:1494-1502.e1. [PMID: 24440221 DOI: 10.1016/j.cgh.2013.12.035] [Cited by in Crossref: 85] [Cited by in F6Publishing: 67] [Article Influence: 12.1] [Reference Citation Analysis]
187 Cosnes J, Bourrier A, Nion-Larmurier I, Sokol H, Beaugerie L, Seksik P. Factors affecting outcomes in Crohn's disease over 15 years. Gut. 2012;61:1140-1145. [PMID: 22387526 DOI: 10.1136/gutjnl-2011-301971] [Cited by in Crossref: 71] [Cited by in F6Publishing: 55] [Article Influence: 7.9] [Reference Citation Analysis]
188 Beelen EMJ, van der Woude CJ, Pierik MJ, Hoentjen F, de Boer NK, Oldenburg B, van der Meulen AE, Ponsioen CIJ, Dijkstra G, Bruggink AH, Erler NS, Schouten WR, de Vries AC; Dutch Initiative on Crohn's and Colitis (ICC). Decreasing Trends in Intestinal Resection and Re-Resection in Crohn's Disease: A Nationwide Cohort Study. Ann Surg 2021;273:557-63. [PMID: 31188225 DOI: 10.1097/SLA.0000000000003395] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
189 Welsch T, Hinz U, Löffler T, Muth G, Herfarth C, Schmidt J, Kienle P. Early re-laparotomy for post-operative complications is a significant risk factor for recurrence after ileocaecal resection for Crohn’s disease. Int J Colorectal Dis 2007;22:1043-9. [DOI: 10.1007/s00384-007-0309-8] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
190 Rahier JF, Ben-Horin S, Chowers Y, Conlon C, De Munter P, D’Haens G, Domènech E, Eliakim R, Eser A, Frater J. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2009;3:47-91. [PMID: 21172250 DOI: 10.1016/j.crohns.2009.02.010] [Cited by in Crossref: 353] [Cited by in F6Publishing: 303] [Article Influence: 29.4] [Reference Citation Analysis]
191 Fu YT, Hong T, Round A, Bressler B. Impact of medical therapy on patients with Crohn's disease requiring surgical resection. World J Gastroenterol 2014;20:11808-14. [PMID: 25206286 DOI: 10.3748/wjg.v20.i33.11808] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
192 Etchevers MJ, Ordás I, Ricart E. Optimizing the Use of Tumour Necrosis Factor Inhibitors in Crohnʼs Disease: A Practical Approach. Drugs 2010;70:109-20. [DOI: 10.2165/11533700-000000000-00000] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
193 Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut 2007;56:453-5. [PMID: 17369375 DOI: 10.1136/gut.2005.088732] [Cited by in Crossref: 196] [Cited by in F6Publishing: 167] [Article Influence: 14.0] [Reference Citation Analysis]
194 Coenen S, Weyts E, Jorissen C, De Munter P, Noman M, Ballet V, Vermeire S, Van Assche G, Ferrante M. Effects of Education and Information on Vaccination Behavior in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis. 2017;23:318-324. [PMID: 28079621 DOI: 10.1097/mib.0000000000001013] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 5.7] [Reference Citation Analysis]
195 Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV Jr. Risk factors associated with progression to intestinal complications of Crohn's disease in a population-based cohort. Gastroenterology. 2010;139:1147-1155. [PMID: 20637205 DOI: 10.1053/j.gastro.2010.06.070] [Cited by in Crossref: 388] [Cited by in F6Publishing: 326] [Article Influence: 35.3] [Reference Citation Analysis]
196 Dewit O, Starkel P, Roblin X. Thiopurine metabolism monitoring: implications in inflammatory bowel diseases. Eur J Clin Invest. 2010;40:1037-1047. [PMID: 20629710 DOI: 10.1111/j.1365-2362.2010.02346.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
197 Malgras B, Pautrat K, Dray X, Pasquier P, Valleur P, Pocard M, Soyer P. Multidisciplinary Management of Gastrointestinal Fibrotic Stenosis in Crohn’s Disease. Dig Dis Sci 2015;60:1152-68. [DOI: 10.1007/s10620-014-3421-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
198 Irwin J, Ferguson E, Simms LA, Hanigan K, Carbonnel F, Radford-Smith G. A rolling phenotype in Crohn's disease. PLoS One 2017;12:e0174954. [PMID: 28384331 DOI: 10.1371/journal.pone.0174954] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
199 Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology. 2006;130:650-656. [PMID: 16530505 DOI: 10.1053/j.gastro.2005.12.019] [Cited by in Crossref: 580] [Cited by in F6Publishing: 504] [Article Influence: 38.7] [Reference Citation Analysis]
200 Lahat A, Chowers Y. The patient with recurrent (sub) obstruction due to Crohn's disease. Best Practice & Research Clinical Gastroenterology 2007;21:427-44. [DOI: 10.1016/j.bpg.2007.02.001] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
201 Masterson JC, McNamee EN, Jedlicka P, Fillon S, Ruybal J, Hosford L, Rivera-Nieves J, Lee JJ, Furuta GT. CCR3 Blockade Attenuates Eosinophilic Ileitis and Associated Remodeling. Am J Pathol 2011;179:2302-14. [PMID: 21945903 DOI: 10.1016/j.ajpath.2011.07.039] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
202 Shergill AK, Terdiman JP. Controversies in the treatment of Crohn's disease: the case for an accelerated step-up treatment approach. World J Gastroenterol 2008;14:2670-7. [PMID: 18461652 DOI: 10.3748/wjg.14.2670] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 11] [Article Influence: 1.2] [Reference Citation Analysis]
203 Osterman MT, Sandborn WJ, Colombel JF, Robinson AM, Lau W, Huang B, Pollack PF, Thakkar RB, Lewis JD. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease. Gastroenterology. 2014;146:941-949. [PMID: 24361468 DOI: 10.1053/j.gastro.2013.12.025] [Cited by in Crossref: 125] [Cited by in F6Publishing: 106] [Article Influence: 15.6] [Reference Citation Analysis]
204 Swoger JM, Regueiro M. Preventive therapy in postoperative Crohn's disease. Curr Opin Gastroenterol. 2010;26:337-343. [PMID: 20571386 DOI: 10.1097/MOG.0b013e328338f724] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
205 Toh JW, Wang N, Young CJ, Rickard MJ, Keshava A, Stewart P, Kariyawasam V, Leong R. Major Abdominal and Perianal Surgery in Crohn’s Disease: Long-term Follow-up of Australian Patients With Crohn’s Disease. Diseases of the Colon & Rectum 2018;61:67-76. [DOI: 10.1097/dcr.0000000000000975] [Cited by in Crossref: 13] [Cited by in F6Publishing: 4] [Article Influence: 4.3] [Reference Citation Analysis]
206 Bewtra M, Su C, Lewis JD. Trends in hospitalization rates for inflammatory bowel disease in the United States. Clin Gastroenterol Hepatol. 2007;5:597-601. [PMID: 17382602 DOI: 10.1016/j.cgh.2007.01.015] [Cited by in Crossref: 99] [Cited by in F6Publishing: 93] [Article Influence: 7.1] [Reference Citation Analysis]
207 Stidham RW, Cross RK. Endoscopy and cross-sectional imaging for assessing Crohn׳s disease activity. Tech Gastrointest Endosc 2016;18:123-30. [PMID: 28458507 DOI: 10.1016/j.tgie.2016.08.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
208 Pallotta N, Vincoli G, Pezzotti P, Giovannone M, Gigliozzi A, Badiali D, Vernia P, Corazziari ES. A risk score system to timely manage treatment in Crohn's disease: a cohort study. BMC Gastroenterol 2018;18:164. [PMID: 30400823 DOI: 10.1186/s12876-018-0889-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
209 Rieder F, Schleder S, Wolf A, Dirmeier A, Strauch U, Obermeier F, Lopez R, Spector L, Fire E, Yarden J. Serum anti-glycan antibodies predict complicated Crohn’s disease behavior: a cohort study. Inflamm Bowel Dis. 2010;16:1367-1375. [PMID: 20024902 DOI: 10.1002/ibd.21179] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 5.5] [Reference Citation Analysis]
210 Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007;56:453-455. [PMID: 17369375 DOI: 10.1136/gut.2005.088732.] [Reference Citation Analysis]
211 Ravikumar B, Sarkar S, Davies JE, Futter M, Garcia-Arencibia M, Green-Thompson ZW, Jimenez-Sanchez M, Korolchuk VI, Lichtenberg M, Luo S, Massey DC, Menzies FM, Moreau K, Narayanan U, Renna M, Siddiqi FH, Underwood BR, Winslow AR, Rubinsztein DC. Regulation of mammalian autophagy in physiology and pathophysiology. Physiol Rev. 2010;90:1383-1435. [PMID: 20959619 DOI: 10.1152/physrev.00030.2009] [Cited by in Crossref: 1202] [Cited by in F6Publishing: 1090] [Article Influence: 109.3] [Reference Citation Analysis]
212 [DOI: 10.1101/424820] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
213 Funayama Y, Takahashi K, Sasaki I. Surgical management in intestinal Crohn’s disease. Clin J Gastroenterol 2010;3:1-5. [DOI: 10.1007/s12328-009-0129-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
214 Kerur B, Machan JT, Shapiro JM, Cerezo CS, Markowitz J, Mack DR, Griffiths AM, Otley AR, Pfefferkorn MD, Rosh JR, Keljo DJ, Boyle B, Oliva-Hemker M, Kay MH, Saeed SA, Grossman AB, Sudel B, Kappelman MD, Schaefer M, Tomer G, Bousvaros A, Lerer T, Hyams JS, LeLeiko NS. Biologics Delay Progression of Crohn's Disease, but Not Early Surgery, in Children. Clin Gastroenterol Hepatol. 2018;16:1467-1473. [PMID: 29486253 DOI: 10.1016/j.cgh.2018.02.027] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 6.7] [Reference Citation Analysis]
215 Devlin SM, Panaccione R. Evolving inflammatory bowel disease treatment paradigms: top-down versus step-up. Med Clin North Am. 2010;94:1-18. [PMID: 19944795 DOI: 10.1016/j.mcna.2009.08.017] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
216 Tamboli CP, Doman DB, Patel A. Current and future role of biomarkers in Crohn’s disease risk assessment and treatment. Clin Exp Gastroenterol. 2011;4:127-140. [PMID: 21753895 DOI: 10.2147/ceg.s18187] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
217 Hu S, Png E, Gowans M, Ong DEH, de Sessions PF, Song J, Nagarajan N. Ectopic gut colonization: a metagenomic study of the oral and gut microbiome in Crohn's disease. Gut Pathog 2021;13:13. [PMID: 33632307 DOI: 10.1186/s13099-021-00409-5] [Reference Citation Analysis]
218 Beaugerie L, Brousse N, Bouvier AM, Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y, Gendre JP. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617-1625. [PMID: 19837455 DOI: 10.1016/s0140-6736(09)61302-7] [Cited by in Crossref: 686] [Cited by in F6Publishing: 182] [Article Influence: 57.2] [Reference Citation Analysis]
219 Lawrance IC, Rogler G, Bamias G, Breynaert C, Florholmen J, Pellino G, Reif S, Speca S, Latella G. Cellular and Molecular Mediators of Intestinal Fibrosis. J Crohns Colitis 2017;11:1491-503. [PMID: 25306501 DOI: 10.1016/j.crohns.2014.09.008] [Cited by in Crossref: 29] [Cited by in F6Publishing: 49] [Article Influence: 9.7] [Reference Citation Analysis]
220 Smith MA, Blaker P, Marinaki AM, Anderson SH, Irving PM, Sanderson JD. Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol. J Crohns Colitis. 2012;6:905-912. [PMID: 22386736 DOI: 10.1016/j.crohns.2012.02.007] [Cited by in Crossref: 75] [Cited by in F6Publishing: 60] [Article Influence: 8.3] [Reference Citation Analysis]
221 Sandborn WJ. Initial combination therapy in early Crohn's disease. Lancet. 2008;371:635-636. [PMID: 18295013 DOI: 10.1016/S0140-6736(08)60285-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
222 Ansari A, Arenas M, Greenfield SM, Morris D, Lindsay J, Gilshenan K, Smith M, Lewis C, Marinaki A, Duley J, Sanderson J. Prospective evaluation of the pharmacogenetics of azathioprine in the treatment of inflammatory bowel disease. Alimentary Pharmacology & Therapeutics 2008;28:973-83. [DOI: 10.1111/j.1365-2036.2008.03788.x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 102] [Article Influence: 8.7] [Reference Citation Analysis]
223 Gasparetto M, Angriman I, Guariso G. The multidisciplinary health care team in the management of stenosis in Crohn's disease. J Multidiscip Healthc 2015;8:167-79. [PMID: 25878504 DOI: 10.2147/JMDH.S38729] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
224 Atreya R, Neurath MF. New therapeutic strategies for treatment of inflammatory bowel disease. Mucosal Immunol 2008;1:175-82. [DOI: 10.1038/mi.2008.7] [Cited by in Crossref: 52] [Cited by in F6Publishing: 50] [Article Influence: 4.0] [Reference Citation Analysis]
225 Gapasin J, Van Langenberg DR, Holtmann G, Hetzel DJ, Andrews JM. Potentially avoidable surgery in inflammatory bowel disease: what proportion of patients come to resection without optimal preoperative therapy? A guidelines-based audit. Intern Med J 2012;42:e84-8. [PMID: 20681962 DOI: 10.1111/j.1445-5994.2010.02328.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
226 Vernier-Massouille G, Cosnes J, Lemann M, Marteau P, Reinisch W, Laharie D, Cadiot G, Bouhnik Y, De Vos M, Boureille A. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine. Gut. 2007;56:1404-1409. [PMID: 17504943 DOI: 10.1136/gut.2006.114363] [Cited by in Crossref: 114] [Cited by in F6Publishing: 92] [Article Influence: 8.1] [Reference Citation Analysis]
227 Banerjee R, Pal P, Girish BG, Reddy DN. Risk factors for diagnostic delay in Crohn's disease and their impact on long-term complications: how do they differ in a tuberculosis endemic region? Aliment Pharmacol Ther 2018;47:1367-74. [DOI: 10.1111/apt.14617] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
228 Schmidt C, Lautenschlaeger C, Collnot E, Schumann M, Bojarski C, Schulzke J, Lehr C, Stallmach A. Nano- and microscaled particles for drug targeting to inflamed intestinal mucosa—A first in vivo study in human patients. Journal of Controlled Release 2013;165:139-45. [DOI: 10.1016/j.jconrel.2012.10.019] [Cited by in Crossref: 130] [Cited by in F6Publishing: 115] [Article Influence: 16.3] [Reference Citation Analysis]
229 Chatu S, Saxena S, Subramanian V, Curcin V, Yadegarfar G, Gunn L, Majeed A, Pollok RC. The impact of timing and duration of thiopurine treatment on first intestinal resection in Crohn's disease: national UK population-based study 1989-2010. Am J Gastroenterol 2014;109:409-16. [PMID: 24469612 DOI: 10.1038/ajg.2013.462] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 7.0] [Reference Citation Analysis]
230 San-Miguel B, Crespo I, Kretzmann NA, Mauriz JL, Marroni N, Tuñón MJ, González-Gallego J. Glutamine prevents fibrosis development in rats with colitis induced by 2,4,6-trinitrobenzene sulfonic acid. J Nutr. 2010;140:1065-1071. [PMID: 20410082 DOI: 10.3945/jn.110.121525] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.5] [Reference Citation Analysis]
231 Kalman TD, Everhov ÅH, Nordenvall C, Sachs MC, Halfvarson J, Ekbom A, Ludvigsson JF, Myrelid P, Olén O. Decrease in primary but not in secondary abdominal surgery for Crohn's disease: nationwide cohort study, 1990–2014. British Journal of Surgery 2020;107:1529-38. [DOI: 10.1002/bjs.11659] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
232 Latella G, Fiocchi C, Caprilli R. Late-breaking news from the "4th International Meeting on Inflammatory Bowel Diseases" Capri, 2006. Inflamm Bowel Dis 2007;13:1031-50. [PMID: 17309072 DOI: 10.1002/ibd.20127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
233 Mullier F, Rahier J, Maignen F, Cornet Y, Graux C, Chatelain C, Chatelain B, Dogne J. A Case of Therapy-Related Myeloid Neoplasm in a Patient with Crohn’s Disease Treated with Azathioprine. Acta Haematol 2012;128:1-6. [DOI: 10.1159/000337046] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
234 Reenaers C, Belaiche J, Louis E. Impact of medical therapies on inflammatory bowel disease complication rate. World J Gastroenterol. 2012;18:3823-3827. [PMID: 22876033 DOI: 10.3748/wjg.v18.i29.3823] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
235 Swoger JM, Regueiro M. Postoperative Crohn's disease: how can we prevent it? Expert Rev Clin Immunol. 2010;6:501-504. [PMID: 20594119 DOI: 10.1586/eci.10.33] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
236 Eisner F, Küper MA, Ziegler F, Zieker D, Königsrainer A, Glatzle J. Impact of perioperative immunosuppressive medication on surgical outcome in Crohn's Disease (CD). Z Gastroenterol 2014;52:436-40. [PMID: 24824908 DOI: 10.1055/s-0033-1356347] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
237 De Cruz P, Kamm MA, Prideaux L, Allen PB, Desmond PV. Postoperative recurrent luminal Crohn's disease: a systematic review. Inflamm Bowel Dis 2012;18:758-77. [PMID: 21830279 DOI: 10.1002/ibd.21825] [Cited by in Crossref: 122] [Cited by in F6Publishing: 100] [Article Influence: 12.2] [Reference Citation Analysis]
238 Nguyen GC, Nugent Z, Shaw S, Bernstein CN. Outcomes of patients with Crohn’s disease improved from 1988 to 2008 and were associated with increased specialist care. Gastroenterology. 2011;141:90-97. [PMID: 21458455 DOI: 10.1053/j.gastro.2011.03.050] [Cited by in Crossref: 112] [Cited by in F6Publishing: 106] [Article Influence: 11.2] [Reference Citation Analysis]
239 Zhang S, Langer R, Traverso G. Nanoparticulate Drug Delivery Systems Targeting Inflammation for Treatment of Inflammatory Bowel Disease. Nano Today 2017;16:82-96. [PMID: 31186671 DOI: 10.1016/j.nantod.2017.08.006] [Cited by in Crossref: 56] [Cited by in F6Publishing: 43] [Article Influence: 14.0] [Reference Citation Analysis]
240 Hanauer SB. Positioning biologic agents in the treatment of Crohn's disease. Inflamm Bowel Dis 2009;15:1570-82. [PMID: 19309716 DOI: 10.1002/ibd.20918] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
241 Boschetti G, Nancey S, Daniel F, Pariente B, Lerebours E, Duclos B, Bourreille A, Cadiot G, Fumery M, Moreau J, Marteau P, Bouhnik Y, Louis E, Flourié B; GETAID. Costs of Crohn's Disease According to Severity States in France: A Prospective Observational Study and Statistical Modeling over 10 Years. Inflamm Bowel Dis 2016;22:2924-32. [PMID: 27846194 DOI: 10.1097/MIB.0000000000000967] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
242 El-Hachem S, Regueiro M. Postoperative Crohn's disease: prevention and treatment. Expert Rev Gastroenterol Hepatol 2009;3:249-56. [PMID: 19485807 DOI: 10.1586/egh.09.21] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
243 Dittrich AE, Sutton RT, Haynes K, Wang H, Fedorak RN, Kroeker KI. Incidence Rates for Surgery in Crohn’s Disease Have Decreased: A Population-based Time-trend Analysis. Inflammatory Bowel Diseases 2020;26:1909-16. [DOI: 10.1093/ibd/izz315] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
244 Fernandes C, Allocca M, Danese S, Fiorino G. Progress with anti-tumor necrosis factor therapeutics for the treatment of inflammatory bowel disease. Immunotherapy 2015;7:175-90. [PMID: 25713992 DOI: 10.2217/imt.14.105] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
245 van Loo ES, Vosseberg NW, van der Heide F, Pierie JE, van der Linde K, Ploeg RJ, Dijkstra G, Nieuwenhuijs VB. Thiopurines Are Associated with a Reduction in Surgical Re-resections in Patients with Crohnʼs Disease: A Long-term Follow-up Study in a Regional and Academic Cohort. Inflammatory Bowel Diseases 2013;19:2801-8. [DOI: 10.1097/01.mib.0000435758.97952.a8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
246 Berg DR, Colombel JF, Ungaro R. The Role of Early Biologic Therapy in Inflammatory Bowel Disease. Inflamm Bowel Dis 2019;25:1896-905. [PMID: 30934053 DOI: 10.1093/ibd/izz059] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 31.0] [Reference Citation Analysis]
247 Bettenworth D, Rieder F. Medical therapy of stricturing Crohn’s disease: what the gut can learn from other organs - a systematic review. Fibrogenesis Tissue Repair. 2014;7:5. [PMID: 24678903 DOI: 10.1186/1755-1536-7-5] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 7.0] [Reference Citation Analysis]
248 Rivière P, Vermeire S, Irles-depe M, Van Assche G, Rutgeerts P, Denost Q, Wolthuis A, D’hoore A, Laharie D, Ferrante M. Rates of Postoperative Recurrence of Crohn’s Disease and Effects of Immunosuppressive and Biologic Therapies. Clinical Gastroenterology and Hepatology 2021;19:713-720.e1. [DOI: 10.1016/j.cgh.2020.03.064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
249 Auzolle C, Nancey S, Tran-minh M, Buisson A, Pariente B, Stefanescu C, Fumery M, Marteau P, Treton X, Hammoudi N, Jouven X, Seksik P, Allez M; REMIND Study Group Investigators. Male gender, active smoking and previous intestinal resection are risk factors for post-operative endoscopic recurrence in Crohn's disease: results from a prospective cohort study. Aliment Pharmacol Ther 2018;48:924-32. [DOI: 10.1111/apt.14944] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
250 Luglio G, Rispo A, Imperatore N, Giglio MC, Amendola A, Tropeano FP, Peltrini R, Castiglione F, De Palma GD, Bucci L. Surgical Prevention of Anastomotic Recurrence by Excluding Mesentery in Crohn's Disease: The SuPREMe-CD Study - A Randomized Clinical Trial. Ann Surg 2020;272:210-7. [PMID: 32675483 DOI: 10.1097/SLA.0000000000003821] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 25.0] [Reference Citation Analysis]
251 Dhyani M, Joshi N, Bemelman WA, Gee MS, Yajnik V, D'Hoore A, Traverso G, Donowitz M, Mostoslavsky G, Lu TK, Lineberry N, Niessen HG, Peer D, Braun J, Delaney CP, Dubinsky MC, Guillory AN, Pereira M, Shtraizent N, Honig G, Polk DB, Hurtado-Lorenzo A, Karp JM, Michelassi F. Challenges in IBD Research: Novel Technologies. Inflamm Bowel Dis 2019;25:S24-30. [PMID: 31095703 DOI: 10.1093/ibd/izz077] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
252 Kasparek MS, Glatzle J, Mueller MH, Schneider A, Koenigsrainer A, Kreis ME. Postoperative Complications have Little Influence on Long-term Quality of Life in Crohn’s Patients. J Gastrointest Surg 2008;12:569-76. [DOI: 10.1007/s11605-007-0412-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
253 Elriz K, Palascak-Juif V, Joly F, Seguy D, Beau P, Chambrier C, Boncompain M, Fontaine E, Laharie D, Savoye G, Lerebours E. Crohn's disease patients with chronic intestinal failure receiving long-term parenteral nutrition: a cross-national adult study. Aliment Pharmacol Ther 2011;34:931-40. [PMID: 21848855 DOI: 10.1111/j.1365-2036.2011.04806.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
254 Leombruno JP, Nguyen GC, Grootendorst P, Juurlink D, Einarson T. Hospitalization and surgical rates in patients with Crohn’s disease treated with infliximab: a matched analysis. Pharmacoepidemiol Drug Saf. 2011;20:838-848. [PMID: 21688345 DOI: 10.1002/pds.2132] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 2.5] [Reference Citation Analysis]
255 Magro F, Barreiro-de Acosta M, Lago P, Carpio D, Cotter J, Echarri A, Gonçalves R, Pereira S, Carvalho L, Lorenzo A, Barros L, Castro J, Dias JA, Rodrigues S, Portela F, Dias C, da Costa-pereira A. Clinical practice in Crohn's disease in bordering regions of two countries: Different medical options, distinct surgical events. Journal of Crohn's and Colitis 2010;4:301-11. [DOI: 10.1016/j.crohns.2009.12.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
256 Ricart E, García-Bosch O, Ordás I, Panés J. Are we giving biologics too late? The case for early versus late use. World J Gastroenterol 2008;14:5523-7. [PMID: 18810770 DOI: 10.3748/wjg.14.5523] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
257 Rieder F, Schleder S, Wolf A, Dirmeier A, Strauch U, Obermeier F, Lopez R, Spector L, Fire E, Yarden J. Association of the novel serologic anti-glycan antibodies anti-laminarin and anti-chitin with complicated Crohn’s disease behavior. Inflamm Bowel Dis. 2010;16:263-274. [PMID: 19653286 DOI: 10.1002/ibd.21046] [Cited by in Crossref: 65] [Cited by in F6Publishing: 64] [Article Influence: 5.9] [Reference Citation Analysis]
258 Burke JP, Velupillai Y, O'Connell PR, Coffey JC. National trends in intestinal resection for Crohn's disease in the post-biologic era.Int J Colorectal Dis. 2013;28:1401-1406. [PMID: 23604410 DOI: 10.1007/s00384-013-1698-5] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
259 Wengrower D, Zanninelli G, Latella G, Necozione S, Metanes I, Israeli E, Lysy J, Pines M, Papo O, Goldin E. Losartan reduces trinitrobenzene sulphonic acid-induced colorectal fibrosis in rats. Can J Gastroenterol 2012;26:33-9. [PMID: 22288068 DOI: 10.1155/2012/628268] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
260 O'Connor A, Hamlin PJ, Taylor J, Selinger C, Scott N, Ford AC. Postoperative prophylaxis in Crohn's disease after intestinal resection: a retrospective analysis. Frontline Gastroenterol 2017;8:203-9. [PMID: 28839910 DOI: 10.1136/flgastro-2016-100749] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
261 Van Assche G, Vermeire S, Rutgeerts P. The potential for disease modification in Crohn's disease. Nat Rev Gastroenterol Hepatol. 2010;7:79-85. [PMID: 20134489 DOI: 10.1038/nrgastro.2009.220] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 5.3] [Reference Citation Analysis]
262 Li Y, Stocchi L, Shen B, Liu X, Remzi FH. Salvage surgery after failure of endoscopic balloon dilatation versus surgery first for ileocolonic anastomotic stricture due to recurrent Crohn's disease. Br J Surg 2015;102:1418-25; discussion 1425. [PMID: 26313750 DOI: 10.1002/bjs.9906] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 4.2] [Reference Citation Analysis]
263 Prideaux L, Kamm MA, De Cruz P, Williams J, Bell SJ, Connell WR, Brown SJ, Lust M, Desmond PV, Chan H. Comparison of clinical characteristics and management of inflammatory bowel disease in Hong Kong versus Melbourne. J Gastroenterol Hepatol. 2012;27:919-927. [PMID: 22098103 DOI: 10.1111/j.1440-1746.2011.06984.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 2.8] [Reference Citation Analysis]
264 Xiong Y, Wang GZ, Zhou JQ, Xia BQ, Wang XY, Jiang B. Serum antibodies to microbial antigens for Crohn’s disease progression: a meta-analysis. Eur J Gastroenterol Hepatol. 2014;26:733-742. [PMID: 24901819 DOI: 10.1097/meg.0000000000000102] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
265 Indar AA, Young-fadok TM, Heppell J, Efron JE. Effect of Perioperative Immunosuppressive Medication on Early Outcome in Crohn’s Disease Patients. World J Surg 2009;33:1049-52. [DOI: 10.1007/s00268-009-9957-x] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 4.4] [Reference Citation Analysis]
266 Camus M, Seksik P, Bourrier A, Nion-Larmurier I, Sokol H, Baumer P, Beaugerie L, Cosnes J. Long-term outcome of patients with Crohn's disease who respond to azathioprine. Clin Gastroenterol Hepatol. 2013;11:389-394. [PMID: 23142207 DOI: 10.1016/j.cgh.2012.10.038] [Cited by in Crossref: 48] [Cited by in F6Publishing: 44] [Article Influence: 5.3] [Reference Citation Analysis]
267 Caviglia R, Boskoski I, Cicala M. Maintenance treatment with infliximab for the management of Crohn's disease in adults. Biologics 2009;3:39-49. [PMID: 19707394 DOI: 10.2147/btt.2009.2763] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
268 Kono T, Fichera A. Surgical Treatment for Crohn's Disease: A Role of Kono-S Anastomosis in the West. Clin Colon Rectal Surg 2020;33:335-43. [PMID: 33162837 DOI: 10.1055/s-0040-1714236] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
269 Schnitzler F, Fidder H, Ferrante M, Noman M, Arijs I, Van Assche G, Hoffman I, Van Steen K, Vermeire S, Rutgeerts P. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009;15:1295-301. [PMID: 19340881 DOI: 10.1002/ibd.20927] [Cited by in Crossref: 468] [Cited by in F6Publishing: 403] [Article Influence: 39.0] [Reference Citation Analysis]
270 Safroneeva E, Vavricka SR, Fournier N, Pittet V, Peyrin-biroulet L, Straumann A, Rogler G, Schoepfer AM; the Swiss IBD Cohort Study Group. Impact of the early use of immunomodulators or TNF antagonists on bowel damage and surgery in Crohn's disease. Aliment Pharmacol Ther 2015;42:977-89. [DOI: 10.1111/apt.13363] [Cited by in Crossref: 64] [Cited by in F6Publishing: 44] [Article Influence: 10.7] [Reference Citation Analysis]
271 Ananthakrishnan AN, Korzenik JR, Hur C. Can mucosal healing be a cost-effective endpoint for biologic therapy in Crohn's disease? A decision analysis. Inflamm Bowel Dis. 2013;19:37-44. [PMID: 22416019 DOI: 10.1002/ibd.22951] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
272 Geltzeiler CB, Hart KD, Lu KC, Deveney KE, Herzig DO, Tsikitis VL. Trends in the Surgical Management of Crohn's Disease. J Gastrointest Surg 2015;19:1862-8. [PMID: 26286366 DOI: 10.1007/s11605-015-2911-3] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
273 Rieder F, Latella G, Magro F, Yuksel ES, Higgins PDR, Di Sabatino A, de Bruyn JR, Rimola J, Brito J, Bettenworth D, van Assche G, Bemelman W, d’Hoore A, Pellino G, Dignass AU. European Crohn’s and Colitis Organisation Topical Review on Prediction, Diagnosis and Management of Fibrostenosing Crohn’s Disease. ECCOJC 2016;10:873-85. [DOI: 10.1093/ecco-jcc/jjw055] [Cited by in Crossref: 102] [Cited by in F6Publishing: 87] [Article Influence: 20.4] [Reference Citation Analysis]
274 Papay P, Reinisch W, Ho E, Gratzer C, Lissner D, Herkner H, Riss S, Dejaco C, Miehsler W, Vogelsang H. The impact of thiopurines on the risk of surgical recurrence in patients with Crohn’s disease after first intestinal surgery. Am J Gastroenterol. 2010;105:1158-1164. [PMID: 20010925 DOI: 10.1038/ajg.2009.673] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 4.3] [Reference Citation Analysis]
275 Yamamoto T. Diagnosis and monitoring of postoperative recurrence in Crohn’s disease. Expert Review of Gastroenterology & Hepatology 2014;9:55-66. [DOI: 10.1586/17474124.2014.940318] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
276 Latella G, Di Gregorio J, Flati V, Rieder F, Lawrance IC. Mechanisms of initiation and progression of intestinal fibrosis in IBD. Scand J Gastroenterol. 2015;50:53-65. [PMID: 25523556 DOI: 10.3109/00365521.2014.968863] [Cited by in Crossref: 80] [Cited by in F6Publishing: 72] [Article Influence: 13.3] [Reference Citation Analysis]
277 Wright EK, Kamm MA, Dr Cruz P, Hamilton AL, Ritchie KJ, Bell SJ, Brown SJ, Connell WR, Desmond PV, Liew D. Cost-effectiveness of Crohn's disease post-operative care. World J Gastroenterol 2016;22:3860-8. [PMID: 27076772 DOI: 10.3748/wjg.v22.i14.3860] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
278 Daperno M, Sostegni R, Canaparo R, Serpe L, Lavagna A, Crocellà L, Castagno F, Vernetto A, Rigazio C, Ercole E. Prospective study of the effects of concomitant medications on thiopurine metabolism in inflammatory bowel disease. Aliment Pharmacol Ther. 2009;30:843-853. [PMID: 19650826 DOI: 10.1111/j.1365-2036.2009.04106.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
279 Rieder F, Kessler S, Sans M, Fiocchi C. Animal models of intestinal fibrosis: new tools for the understanding of pathogenesis and therapy of human disease. Am J Physiol Gastrointest Liver Physiol. 2012;303:G786-G801. [PMID: 22878121 DOI: 10.1152/ajpgi.00059.2012] [Cited by in Crossref: 82] [Cited by in F6Publishing: 80] [Article Influence: 9.1] [Reference Citation Analysis]
280 Lawrance IC, Rogler G, Bamias G, Breynaert C, Florholmen J, Pellino G, Reif S, Speca S, Latella G. Cellular and Molecular Mediators of Intestinal Fibrosis. J Crohns Colitis. 2015; Nov 2; Epub ahead of print. [PMID: 25306501 DOI: 10.1016/j.crohns.2014.09.00] [Reference Citation Analysis]
281 Mahlich J, Matsuoka K, Sruamsiri R. Biologic treatment of Japanese patients with inflammatory bowel disease. BMC Gastroenterol 2018;18:160. [PMID: 30384833 DOI: 10.1186/s12876-018-0892-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
282 Danese S, Fiorino G, Peyrin-Biroulet L. Early intervention in Crohn's disease: towards disease modification trials. Gut 2017;66:2179-87. [PMID: 28874419 DOI: 10.1136/gutjnl-2017-314519] [Cited by in Crossref: 46] [Cited by in F6Publishing: 31] [Article Influence: 11.5] [Reference Citation Analysis]
283 Ng CH, Chin YH, Lin SY, Koh JWH, Lieske B, Koh FH, Chong CS, Foo FJ. Kono-S anastomosis for Crohn's disease: a systemic review, meta-analysis, and meta-regression. Surg Today 2021;51:493-501. [PMID: 32894346 DOI: 10.1007/s00595-020-02130-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
284 Benitez JM, Meuwis MA, Reenaers C, Van Kemseke C, Meunier P, Louis E. Role of endoscopy, cross-sectional imaging and biomarkers in Crohn’s disease monitoring. Gut. 2013;62:1806-1816. [PMID: 24203056 DOI: 10.1136/gutjnl-2012-303957] [Cited by in Crossref: 70] [Cited by in F6Publishing: 57] [Article Influence: 10.0] [Reference Citation Analysis]
285 Benchimol EI, Guttmann A, To T, Rabeneck L, Griffiths AM. Changes to surgical and hospitalization rates of pediatric inflammatory bowel disease in Ontario, Canada (1994-2007). Inflamm Bowel Dis. 2011;17:2153-2161. [PMID: 21910177 DOI: 10.1002/ibd.21591] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 4.8] [Reference Citation Analysis]
286 Ye BD, Yang SK, Cho YK, Park SH, Yang DH, Yoon SM, Kim KJ, Byeon JS, Myung SJ, Yu CS. Clinical features and long-term prognosis of Crohn’s disease in Korea. Scand J Gastroenterol. 2010;45:1178-1185. [PMID: 20560811 DOI: 10.3109/00365521.2010.497936] [Cited by in Crossref: 81] [Cited by in F6Publishing: 75] [Article Influence: 8.1] [Reference Citation Analysis]
287 Siassi M, Weiger A, Hohenberger W, Kessler H. Changes in surgical therapy for Crohn’s disease over 33 years: a prospective longitudinal study. Int J Colorectal Dis. 2007;22:319-324. [PMID: 16733647 DOI: 10.1007/s00384-006-0150-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
288 Kwak MS, Kim DH, Park SJ, Kim TI, Hong SP, Kim WH, Cheon JH. Efficacy of early immunomodulator therapy on the outcomes of Crohn's disease. BMC Gastroenterol. 2014;14:85. [PMID: 24886458 DOI: 10.1186/1471-230x-14-85] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
289 Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, Harrison J, Plevy SE. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology. 2009;136:441-450.e1; quiz 716. [PMID: 19109962 DOI: 10.1053/j.gastro.2008.10.051] [Cited by in Crossref: 407] [Cited by in F6Publishing: 315] [Article Influence: 31.3] [Reference Citation Analysis]
290 Ananthakrishnan AN, McGinley EL, Binion DG, Saeian K. A nationwide analysis of changes in severity and outcomes of inflammatory bowel disease hospitalizations. J Gastrointest Surg. 2011;15:267-276. [PMID: 21108015 DOI: 10.1007/s11605-010-1396-3] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 3.9] [Reference Citation Analysis]
291 Cummins EP, Doherty GA, Taylor CT. Hydroxylases as therapeutic targets in inflammatory bowel disease. Lab Invest 2013;93:378-83. [PMID: 23419710 DOI: 10.1038/labinvest.2013.9] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
292 Zhu Y, Zhou W, Qi W, Liu W, Chen M, Zhu H, Xiang J, Xie Q, Chen P. Body mass index is a practical preoperative nutritional index for postoperative infectious complications after intestinal resection in patients with Crohn's disease.Medicine (Baltimore). 2017;96:e7113. [PMID: 28591060 DOI: 10.1097/MD.0000000000007113] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
293 van der Woude CJ, Hommes DW. Are we ready for top-down therapy for inflammatory bowel diseases: pro. Expert Review of Gastroenterology & Hepatology 2014;1:243-8. [DOI: 10.1586/17474124.1.2.243] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
294 Moffatt D, Bernstein CN. State-of-the-Art Medical Therapy of the Adult Patient with IBD: The Immunomodulators. In: Cohen RD, editor. Inflammatory Bowel Disease. Totowa: Humana Press; 2011. pp. 93-110. [DOI: 10.1007/978-1-60327-433-3_7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
295 Vernier-Massouille G, Balde M, Salleron J, Turck D, Dupas JL, Mouterde O, Merle V, Salomez JL, Branche J, Marti R, Lerebours E, Cortot A, Gower-Rousseau C, Colombel JF. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology. 2008;135:1106-1113. [PMID: 18692056 DOI: 10.1053/j.gastro.2008.06.079] [Cited by in Crossref: 390] [Cited by in F6Publishing: 332] [Article Influence: 30.0] [Reference Citation Analysis]
296 Qiu Y, Mao R, Chen B, He Y, Zeng Z, Chen M. Systematic Review with Meta-analysis of Prospective Studies: Anti-tumour Necrosis Factor for Prevention of Postoperative Crohn’s Disease Recurrence. ECCOJC 2015;9:918-27. [DOI: 10.1093/ecco-jcc/jjv112] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
297 Caruso A, Angriman I, Scarpa M, D’incà R, Mescoli C, Rudatis M, Sturniolo GC, Schifano G, Lacognata C. Diffusion-weighted magnetic resonance for assessing fibrosis in Crohn’s disease. Abdom Radiol 2020;45:2327-35. [DOI: 10.1007/s00261-019-02167-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
298 Chang CW, Wong JM, Tung CC, Shih IL, Wang HY, Wei SC. Intestinal stricture in Crohn’s disease. Intest Res. 2015;13:19-26. [PMID: 25691840 DOI: 10.5217/ir.2015.13.1.19] [Cited by in Crossref: 48] [Cited by in F6Publishing: 29] [Article Influence: 8.0] [Reference Citation Analysis]
299 O’brien SJ, Chen RC, Stephen VT, Jorden J, Farmer R, Manek S, Schmidt M, Pan J, Rai SN, Galandiuk S. Preoperative Opioid Prescription Is Associated With Major Complications in Patients With Crohn’s Disease Undergoing Elective Ileocolic Resection. Diseases of the Colon & Rectum 2020;63:1090-101. [DOI: 10.1097/dcr.0000000000001571] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
300 Xu Z, Davis HM, Zhou H. Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety. J Clin Pharmacol 2015;55 Suppl 3:S60-74. [PMID: 25707965 DOI: 10.1002/jcph.380] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 5.0] [Reference Citation Analysis]
301 González-Lama Y, Suárez C, González-Partida I, Calvo M, Matallana V, de la Revilla J, Magaz M, Bernardo C, Agudo B, Ibarrola P, Relea L, Arévalo J, Vera MI, Abreu L. Timing of Thiopurine or Anti-TNF Initiation Is Associated with the Risk of Major Abdominal Surgery in Crohn's Disease: A Retrospective Cohort Study. J Crohns Colitis 2016;10:55-60. [PMID: 26520164 DOI: 10.1093/ecco-jcc/jjv187] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
302 McLarren KW, Cole AE, Weisser SB, Voglmaier NS, Conlin VS, Jacobson K, Popescu O, Boucher JL, Sly LM. SHIP-deficient mice develop spontaneous intestinal inflammation and arginase-dependent fibrosis. Am J Pathol 2011;179:180-8. [PMID: 21640975 DOI: 10.1016/j.ajpath.2011.03.018] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.4] [Reference Citation Analysis]
303 Andrews JM, Travis SP, Gibson PR, Gasche C. Systematic review: does concurrent therapy with 5-ASA and immunomodulators in inflammatory bowel disease improve outcomes? Aliment Pharmacol Ther. 2009;29:459-469. [PMID: 19077129 DOI: 10.1111/j.1365-2036.2008.03915.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
304 Lee CK. [Ideal vaccination strategy in inflammatory bowel disease]. Korean J Gastroenterol 2015;65:159-64. [PMID: 25797379 DOI: 10.4166/kjg.2015.65.3.159] [Reference Citation Analysis]
305 Meregaglia M, Banks H, Fattore G. Hospital Burden and Gastrointestinal Surgery in Inflammatory Bowel Disease Patients in Italy: A Retrospective Observational Study. J Crohns Colitis 2015;9:853-62. [PMID: 26069194 DOI: 10.1093/ecco-jcc/jjv104] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
306 Rosh JR. Alternative strategies for the use of infliximab in pediatric inflammatory bowel disease. Curr Gastroenterol Rep 2008;10:302-7. [DOI: 10.1007/s11894-008-0060-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
307 Wenger S, Nikolaus S, Howaldt S, Bokemeyer B, Sturm A, Preiss JC, Schoepfer AM, Stallmach A, Schmidt C. Predictors for subsequent need for immunosuppressive therapy in early Crohn's disease. Journal of Crohn's and Colitis 2012;6:21-8. [DOI: 10.1016/j.crohns.2011.06.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
308 Reenaers C, Louis E, Belaiche J. Current directions of biologic therapies in inflammatory bowel disease. Therap Adv Gastroenterol. 2010;3:99-106. [PMID: 21180594 DOI: 10.1177/1756283x09356872] [Cited by in Crossref: 19] [Cited by in F6Publishing: 7] [Article Influence: 1.9] [Reference Citation Analysis]
309 Amiot A, Gornet J, Baudry C, Munoz-bongrand N, Auger M, Simon M, Allez M, Cattan P, Sarfati E, Lémann M. Crohn's disease recurrence after total proctocolectomy with definitive ileostomy. Digestive and Liver Disease 2011;43:698-702. [DOI: 10.1016/j.dld.2011.02.017] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
310 Pulakazhi Venu VK, Alston L, Iftinca MC, Tsai YC, Stephens M, Warriyar V, Rehal S, Hudson GM, Szczepanski H, von der Weid PY, Altier C, Hirota SA. NR4A1 modulates inflammation-associated intestinal fibrosis and dampens fibrogenic signaling in myofibroblasts. Am J Physiol Gastrointest Liver Physiol 2021. [PMID: 34288735 DOI: 10.1152/ajpgi.00338.2019] [Reference Citation Analysis]
311 Kariyawasam VC, Selinger CP, Katelaris PH, Jones DB, Mcdonald C, Barr G, Chapman G, Colliwshaw J, Lunney PC, Middleton K, Wang RR, Huang T, Andrews J, Leong RW. Early Use of Thiopurines or Methotrexate Reduces Major Abdominal and Perianal Surgery in Crohnʼs Disease: . Inflammatory Bowel Diseases 2014;20:1382-90. [DOI: 10.1097/mib.0000000000000119] [Cited by in Crossref: 43] [Cited by in F6Publishing: 8] [Article Influence: 6.1] [Reference Citation Analysis]
312 Ananthakrishnan AN, McGinley EL, Saeian K, Binion DG. Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:976-983. [PMID: 20824818 DOI: 10.1002/ibd.21457] [Cited by in Crossref: 104] [Cited by in F6Publishing: 98] [Article Influence: 9.5] [Reference Citation Analysis]
313 Picco MF, Zubiaurre I, Adluni M, Cangemi JR, Shelton D. Immunomodulators are associated with a lower risk of first surgery among patients with non-penetrating non-stricturing Crohn’s disease. Am J Gastroenterol. 2009;104:2754-2759. [PMID: 19584832 DOI: 10.1038/ajg.2009.387] [Cited by in Crossref: 49] [Cited by in F6Publishing: 41] [Article Influence: 4.1] [Reference Citation Analysis]
314 Lasson A, Strid H, Ohman L, Isaksson S, Olsson M, Rydström B, Ung KA, Stotzer PO. Fecal calprotectin one year after ileocaecal resection for Crohn’s disease--a comparison with findings at ileocolonoscopy. J Crohns Colitis. 2014;8:789-795. [PMID: 24418661 DOI: 10.1016/j.crohns.2013.12.015] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.9] [Reference Citation Analysis]
315 Latella G, Sferra R, Vetuschi A, Zanninelli G, D'Angelo A, Catitti V, Caprilli R, Gaudio E. Prevention of colonic fibrosis by Boswellia and Scutellaria extracts in rats with colitis induced by 2,4,5-trinitrobenzene sulphonic acid. Eur J Clin Invest. 2008;38:410-420. [PMID: 18489401 DOI: 10.1111/j.1365-2362.2008.01955.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.5] [Reference Citation Analysis]
316 Lightner AL. Segmental Resection versus Total Proctocolectomy for Crohn's Colitis: What is the Best Operation in the Setting of Medically Refractory Disease or Dysplasia? Inflamm Bowel Dis. 2018;24:532-538. [PMID: 29462390 DOI: 10.1093/ibd/izx064] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
317 De Cruz P, Bernardi MP, Kamm MA, Allen PB, Prideaux L, Williams J, Johnston MJ, Keck J, Brouwer R, Heriot A. Postoperative recurrence of Crohn’s disease: impact of endoscopic monitoring and treatment step-up. Colorectal Dis. 2013;15:187-197. [PMID: 22757652 DOI: 10.1111/j.1463-1318.2012.03168.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
318 Ananthakrishnan AN, Cagan A, Gainer VS, Cai T, Cheng SC, Savova G, Chen P, Szolovits P, Xia Z, De Jager PL, Shaw SY, Churchill S, Karlson EW, Kohane I, Plenge RM, Murphy SN, Liao KP. Normalization of plasma 25-hydroxy vitamin D is associated with reduced risk of surgery in Crohn's disease. Inflamm Bowel Dis 2013;19:1921-7. [PMID: 23751398 DOI: 10.1097/MIB.0b013e3182902ad9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 80] [Article Influence: 3.7] [Reference Citation Analysis]
319 Amiot A, Setakhr V, Seksik P, Allez M, Treton X, De Vos M, Laharie D, Colombel JF, Abitbol V, Reimund JM, Moreau J, Veyrac M, Flourié B, Cosnes J, Lemann M, Bouhnik Y. Long-term outcome of enterocutaneous fistula in patients with Crohn's disease treated with anti-TNF therapy: a cohort study from the GETAID. Am J Gastroenterol 2014;109:1443-9. [PMID: 25091063 DOI: 10.1038/ajg.2014.183] [Cited by in Crossref: 48] [Cited by in F6Publishing: 35] [Article Influence: 6.9] [Reference Citation Analysis]
320 Nielsen OH, Riis LB, Danese S, Bojesen RD, Soendergaard C. Proximal collagenous gastroenteritides: Clinical management. A systematic review. Annals of Medicine 2014;46:311-7. [DOI: 10.3109/07853890.2014.899102] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
321 Zimmerman LA, Shamberger RC, Valim C, Bousvaros A. The effect of immunomodulators and biologics on indication for surgical bowel resection in children with Crohn's disease. Inflamm Bowel Dis 2014;20:1015-20. [PMID: 24788215 DOI: 10.1097/MIB.0000000000000042] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
322 Nuij VJAA, Peppelenbosch MP, van der Woude CJ, Fuhler GM. Genetic polymorphism in ATG16L1 gene is associated with adalimumab use in inflammatory bowel disease. J Transl Med 2017;15:248. [PMID: 29228965 DOI: 10.1186/s12967-017-1355-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
323 Siegmund B. Medical Therapy of Fibrostenotic Crohn's Disease. Viszeralmedizin 2015;31:259-64. [PMID: 26557834 DOI: 10.1159/000435868] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
324 Kapur S, Hanauer SB. The Evolving Role of Thiopurines in Inflammatory Bowel Disease. Curr Treat Options Gastroenterol 2019;17:420-33. [PMID: 31352659 DOI: 10.1007/s11938-019-00244-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
325 Vegh Z, Burisch J, Pedersen N, Kaimakliotis I, Duricova D, Bortlik M, Vinding KK, Avnstrøm S, Olsen J, Nielsen KR, Katsanos KH, Tsianos EV, Lakatos L, Schwartz D, Odes S, D’incà R, Beltrami M, Kiudelis G, Kupcinskap L, Jucov A, Turcan S, Barros LF, Magro F, Lazar D, Goldis A, de Castro L, Hernandez V, Niewiadomski O, Bell S, Langholz E, Munkholm P, Lakatos PL; for the EpiCom-group. Treatment Steps, Surgery, and Hospitalization Rates During the First Year of Follow-up in Patients with Inflammatory Bowel Diseases from the 2011 ECCO-Epicom Inception Cohort. ECCOJC 2015;9:747-53. [DOI: 10.1093/ecco-jcc/jjv099] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.8] [Reference Citation Analysis]
326 D'haens G, Baert F, van Assche G, Caenepeel P, Vergauwe P, Tuynman H, De Vos M, van Deventer S, Stitt L, Donner A, Vermeire S, Van De Mierop FJ, Coche JR, van der Woude J, Ochsenkühn T, van Bodegraven AA, Van Hootegem PP, Lambrecht GL, Mana F, Rutgeerts P, Feagan BG, Hommes D. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. The Lancet 2008;371:660-7. [DOI: 10.1016/s0140-6736(08)60304-9] [Cited by in Crossref: 845] [Cited by in F6Publishing: 237] [Article Influence: 65.0] [Reference Citation Analysis]
327 Rieder F. The gut microbiome in intestinal fibrosis: environmental protector or provocateur? Sci Transl Med. 2013;5:190ps10. [PMID: 23785034 DOI: 10.1126/scitranslmed.3004731] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
328 Franzè E, Monteleone I, Laudisi F, Rizzo A, Dinallo V, Di Fusco D, Colantoni A, Ortenzi A, Giuffrida P, Di Carlo S, Sica GS, Di Sabatino A, Monteleone G. Cadherin-11 Is a Regulator of Intestinal Fibrosis. J Crohns Colitis 2020;14:406-17. [PMID: 31504344 DOI: 10.1093/ecco-jcc/jjz147] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
329 Stenke E, Bourke B, Knaus U. Crohn's Strictures-Moving Away from the Knife.Front Pediatr. 2017;5:141. [PMID: 28670577 DOI: 10.3389/fped.2017.00141] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
330 Novacek G, Miehsler W, Palkovits J, Reinisch W, Waldhör T, Kapiotis S, Gangl A, Vogelsang H. Resistance to activated protein C is a risk factor for fibrostenosis in Crohn's disease. World J Gastroenterol 2006;12:6026-31. [PMID: 17009403 DOI: 10.3748/wjg.v12.i37.6026] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
331 Andrews JM, Mountifield RE, Van Langenberg DR, Bampton PA, Holtmann GJ. Un-promoted issues in inflammatory bowel disease: opportunities to optimize care. Intern Med J. 2010;40:173-182. [PMID: 19849744 DOI: 10.1111/j.1445-5994.2009.02110.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.7] [Reference Citation Analysis]
332 Rhodes JM, Robinson R, Beales I, Pugh S, Dickinson R, Dronfield M, Speirs CJ, Wilkinson P, Wilkinson SP. Clinical trial: oral prednisolone metasulfobenzoate (Predocol) vs. oral prednisolone for active ulcerative colitis. Aliment Pharmacol Ther 2008;27:228-40. [PMID: 17988236 DOI: 10.1111/j.1365-2036.2007.03569.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
333 Gao X, Yang RP, Chen MH, Xiao YL, He Y, Chen BL, Hu PJ. Risk factors for surgery and postoperative recurrence: analysis of a south China cohort with Crohn's disease. Scand J Gastroenterol. 2012;47:1181-1191. [PMID: 22845663 DOI: 10.3109/00365521.2012.668931] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 2.9] [Reference Citation Analysis]
334 Dubinsky M. Evaluation and Management of the Patient With Suspected Recurrent Crohn's Disease: The Postoperative Crohn's Disease Patient. Am J Gastroenterology 2007;102:S38-40. [DOI: 10.1111/j.1572-0241.2007.01298.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
335 Andus T. Chronisch-entzündliche Darmerkrankungen: Wissenschaft heute – Standard morgen, Koloproktologie UPDATE 2015. coloproctology 2016;38:314-25. [DOI: 10.1007/s00053-015-0064-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
336 Rutgeerts P, Van Assche G, Vermeire S. Review article: Infliximab therapy for inflammatory bowel disease--seven years on. Aliment Pharmacol Ther. 2006;23:451-463. [PMID: 16441465 DOI: 10.1111/j.1365-2036.2006.02786.x] [Cited by in Crossref: 168] [Cited by in F6Publishing: 151] [Article Influence: 11.2] [Reference Citation Analysis]
337 Hoentjen F, Colwell JC, Hanauer SB. Complications of peristomal recurrence of Crohn’s disease: a case report and a review of literature. J Wound Ostomy Continence Nurs. 2012;39:297-301. [PMID: 22552106 DOI: 10.1097/won.0b013e3182487189] [Cited by in Crossref: 11] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
338 Mao R, Doyon G, Gordon IO, Li J, Lin S, Wang J, Le THN, Elias M, Kurada S, Southern B, Olman M, Chen M, Zhao S, Dejanovic D, Chandra J, Mukherjee PK, West G, Van Wagoner DR, Fiocchi C, Rieder F. Activated intestinal muscle cells promote preadipocyte migration: a novel mechanism for creeping fat formation in Crohn's disease. Gut 2021:gutjnl-2020-323719. [PMID: 33468536 DOI: 10.1136/gutjnl-2020-323719] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
339 Behm BW, Bickston SJ. Medical management of Crohn's disease: current therapy and recent advances. Expert Review of Clinical Immunology 2014;2:109-20. [DOI: 10.1586/1744666x.2.1.109] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
340 Murakami Y, Matsui T, Hirai F, Takatsu N, Takaki Y, Nagahama T, Hisabe T, Beppu T, Miyaoka M, Maki S, Takeichi M, Nishimura T, Ueki T, Yao K. EFFICACY OF AZATHIOPRINE IN MILD OR MODERATE RELAPSE IN CROHN'S DISEASE: CLINICAL AND ENDOSCOPIC EVALUATION: AZATHIOPRINE IN RELAPSE OF CROHN'S DISEASE. Digestive Endoscopy 2010;22:25-32. [DOI: 10.1111/j.1443-1661.2009.00914.x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
341 Bakouny Z, Yared F, El Rassy E, Jabbour R, Hallit R, Khoury N, Honein K, Bou Jaoude J. Comparative Efficacy of Anti-TNF Therapies For The Prevention of Postoperative Recurrence of Crohn's Disease: A Systematic Review and Network Meta-Analysis of Prospective Trials. J Clin Gastroenterol 2019;53:409-17. [PMID: 29517709 DOI: 10.1097/MCG.0000000000001006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 10.0] [Reference Citation Analysis]
342 Kotze PG, Magro DO, Saab B, Saab MP, Pinheiro LV, Olandoski M, Ayrizono MLS, Martinez CAR, Coy CSR. Comparison of time until elective intestinal resection regarding previous anti-tumor necrosis factor exposure: a Brazilian study on patients with Crohn's disease. Intest Res. 2018;16:62-68. [PMID: 29422799 DOI: 10.5217/ir.2018.16.1.62] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
343 Li Y, Zuo L, Zhu W, Gong J, Zhang W, Gu L, Guo Z, Cao L, Li N, Li J. Role of exclusive enteral nutrition in the preoperative optimization of patients with Crohn's disease following immunosuppressive therapy. Medicine (Baltimore). 2015;94:e478. [PMID: 25654387 DOI: 10.1097/md.0000000000000478] [Cited by in Crossref: 37] [Cited by in F6Publishing: 16] [Article Influence: 6.2] [Reference Citation Analysis]
344 Singh H, Demers AA, Nugent Z, Mahmud SM, Kliewer EV, Bernstein CN. Risk of cervical abnormalities in women with inflammatory bowel disease: a population-based nested case-control study. Gastroenterology. 2009;136:451-458. [PMID: 18996382 DOI: 10.1053/j.gastro.2008.10.021] [Cited by in Crossref: 74] [Cited by in F6Publishing: 69] [Article Influence: 5.7] [Reference Citation Analysis]
345 Gilletta C, Lewin M, Bourrier A, Nion-Larmurier I, Rajca S, Beaugerie L, Sokol H, Pariente B, Seksik P, Cosnes J. Changes in the Lémann Index Values During the First Years of Crohn's Disease. Clin Gastroenterol Hepatol 2015;13:1633-40.e3. [PMID: 25766650 DOI: 10.1016/j.cgh.2015.02.041] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
346 Chan WPW, Mourad F, Leong RW. Crohn's disease associated strictures. J Gastroenterol Hepatol. 2018;33:998-1008. [PMID: 29427364 DOI: 10.1111/jgh.14119] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 9.3] [Reference Citation Analysis]
347 Billiet T, Ferrante M, Van Assche G. The use of prognostic factors in inflammatory bowel diseases. Curr Gastroenterol Rep. 2014;16:416. [PMID: 25262067 DOI: 10.1007/s11894-014-0416-y] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
348 Kamm MA, Ng SC, De Cruz P, Allen P, Hanauer SB. Practical application of anti-TNF therapy for luminal Crohn’s disease. Inflamm Bowel Dis. 2011;17:2366-2391. [PMID: 21337669 DOI: 10.1002/ibd.21655] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
349 Truffi M, Sorrentino L, Monieri M, Fociani P, Mazzucchelli S, Bonzini M, Zerbi P, Sampietro GM, Di Sabatino A, Corsi F. Inhibition of Fibroblast Activation Protein Restores a Balanced Extracellular Matrix and Reduces Fibrosis in Crohn’s Disease Strictures Ex Vivo. Inflammatory Bowel Diseases 2018;24:332-45. [DOI: 10.1093/ibd/izx008] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 6.3] [Reference Citation Analysis]
350 Speca S, Giusti I, Rieder F, Latella G. Cellular and molecular mechanisms of intestinal fibrosis. World J Gastroenterol. 2012;18:3635-3661. [PMID: 22851857 DOI: 10.3748/wjg.v18.i28.3635] [Cited by in CrossRef: 134] [Cited by in F6Publishing: 120] [Article Influence: 16.8] [Reference Citation Analysis]
351 Rutgeerts P, Vermeire S, Van Assche G. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target? Gut. 2007;56:453-455. [PMID: 17369375 DOI: 10.1136/gut.2005. 088732] [Reference Citation Analysis]
352 Naganuma M, Watanabe M, Hibi T. Safety and usefulness of balloon endoscopy in Crohn's disease patients with postoperative ileal lesions. Journal of Crohn's and Colitis 2011;5:73-4. [DOI: 10.1016/j.crohns.2010.10.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
353 Raselli T, Wyss A, Gonzalez Alvarado MN, Weder B, Mamie C, Spalinger MR, Van Haaften WT, Dijkstra G, Sailer AW, Imenez Silva PH, Wagner CA, Tosevski V, Leibl S, Scharl M, Rogler G, Hausmann M, Misselwitz B. The Oxysterol Synthesising Enzyme CH25H Contributes to the Development of Intestinal Fibrosis. J Crohns Colitis 2019;13:1186-200. [PMID: 31220227 DOI: 10.1093/ecco-jcc/jjz039] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
354 Hashash JG, Regueiro M. A Practical Approach to Preventing Postoperative Recurrence in Crohn’s Disease. Curr Gastroenterol Rep 2016;18. [DOI: 10.1007/s11894-016-0499-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
355 Wibmer AG, Kroesen AJ, Gröne J, Buhr HJ, Ritz JP. Comparison of strictureplasty and endoscopic balloon dilatation for stricturing Crohn’s disease--review of the literature. Int J Colorectal Dis. 2010;25:1149-1157. [PMID: 20628881 DOI: 10.1007/s00384-010-1010-x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 49] [Article Influence: 5.6] [Reference Citation Analysis]
356 Faubion WA, Bousvaros A. Medical Therapy for Refractory Pediatric Crohn’s Disease. Clinical Gastroenterology and Hepatology 2006;4:1199-213. [DOI: 10.1016/j.cgh.2006.05.031] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
357 Egan LJ, Sandborn WJ. Positioning novel biologic, probiotic, and apheresis therapies for crohn’s disease and ulcerative colitis. Curr Gastroenterol Rep 2005;7:485-91. [DOI: 10.1007/s11894-005-0080-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
358 Sands BE. The risks and benefits of early immunosuppression and biological therapy. Dig Dis. 2012;30 Suppl 3:100-106. [PMID: 23295699 DOI: 10.1159/000342731] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
359 Hammoudi N, Cazals-hatem D, Auzolle C, Gardair C, Ngollo M, Bottois H, Nancey S, Pariente B, Buisson A, Treton X, Fumery M, Bezault M, Seksik P, Le Bourhis L, Flejou J, Allez M, Cattan P, Chirica M, Munoz-bongrand N, Corte H, Beaupel N, Catry J, Gornet J, Baudry C, Lourenco N, Maillet M, Tran-minh M, Chardiny V, Grand C, Gergaud B, Bonnet J, Chedouba L, Nisard A, Beaugerie L, Sokol H, Bourrier A, Nion-larmurier I, Kirchgesner J, Quevrain E, Brot L, Chafai N, Lefevre JH, Tiret E, Svrcek M, Guedj N, Panis Y, Magiorri L, Ferron M, Bouhnik Y, Corcos O, Stefanescu C, Marteau P, Dray X, Chaput U, Kaci R, Dubois A, Bommelaer G, Goutte M, Barnich N, Coban D, Godfraind C, Zakeyh JJ, Desreumaux P, Nachury M, Sommeville C, Renaud F, Dupas J, Loreau J, Brazier F, Chatelain D, Attencourt C, Sabbagh C, Leconte M, Boschetti G, Flourié B, François Y, Cotte E, Charlois A, Falgon P, Hadjisavvas H, Moussata D, Chauvenet M, Boyer S, Traverse-glehen A, Hebuterne X, Filippi J, Hofmann P, Rahili A, Patouraux S, Jouven X. Association Between Microscopic Lesions at Ileal Resection Margin and Recurrence After Surgery in Patients With Crohn’s Disease. Clinical Gastroenterology and Hepatology 2020;18:141-149.e2. [DOI: 10.1016/j.cgh.2019.04.045] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
360 Kapur S, Hanauer SB. The Evolving Role of Thiopurines in Inflammatory Bowel Disease. Curr Treat Options Gastro 2019;17:435-48. [DOI: 10.1007/s11938-019-00249-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
361 Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, Patel K, Wolf DC, Safdi M, Colombel JF, Lashner B, Hanauer SB. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006;63:433-442; quiz 464. [PMID: 16500392 DOI: 10.1016/j.gie.2005.08.011] [Cited by in Crossref: 394] [Cited by in F6Publishing: 332] [Article Influence: 26.3] [Reference Citation Analysis]
362 Schreiber S, Colombel JF, Bloomfield R, Nikolaus S, Schölmerich J, Panés J, Sandborn WJ. Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol: an analysis of PRECiSE 2 randomized maintenance trial data. Am J Gastroenterol. 2010;105:1574-1582. [PMID: 20234346 DOI: 10.1038/ajg.2010.78] [Cited by in Crossref: 150] [Cited by in F6Publishing: 127] [Article Influence: 13.6] [Reference Citation Analysis]
363 Moon W, Loftus EV. Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2016;43:863-883. [PMID: 26876431 DOI: 10.1111/apt.13559] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 10.6] [Reference Citation Analysis]
364 Van Assche G, Vermeire S, Rutgeerts P. Endoscopic therapy of strictures in Crohn's disease. Inflamm Bowel Dis 2007;13:356-8; discussion 362-3. [PMID: 17230480 DOI: 10.1002/ibd.20091] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
365 Nanda K, Courtney W, Keegan D, Byrne K, Nolan B, O'Donoghue D, Mulcahy H, Doherty G. Prolonged avoidance of repeat surgery with endoscopic balloon dilatation of anastomotic strictures in Crohn's disease. J Crohns Colitis 2013;7:474-80. [PMID: 22898397 DOI: 10.1016/j.crohns.2012.07.019] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
366 Pigneur B, Seksik P, Viola S, Viala J, Beaugerie L, Girardet JP, Ruemmele FM, Cosnes J. Natural history of Crohn's disease: comparison between childhood- and adult-onset disease. Inflamm Bowel Dis. 2010;16:953-961. [PMID: 19834970 DOI: 10.1002/ibd.21152] [Cited by in Crossref: 158] [Cited by in F6Publishing: 131] [Article Influence: 14.4] [Reference Citation Analysis]
367 Ha C, Dassopoulos T. Thiopurine therapy in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2010;4:575-588. [PMID: 20932143 DOI: 10.1586/egh.10.59] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
368 Rieder F, Bettenworth D, Imai J, Inagaki Y. Intestinal Fibrosis and Liver Fibrosis: Consequences of Chronic Inflammation or Independent Pathophysiology? Inflamm Intest Dis. 2016;1:41-49. [PMID: 29922656 DOI: 10.1159/000445135] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
369 De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, Liew D, Prideaux L, Lawrance IC, Andrews JM, Bampton PA, Gibson PR, Sparrow M, Leong RW, Florin TH, Gearry RB, Radford-Smith G, Macrae FA, Debinski H, Selby W, Kronborg I, Johnston MJ, Woods R, Elliott PR, Bell SJ, Brown SJ, Connell WR, Desmond PV. Crohn's disease management after intestinal resection: a randomised trial. Lancet. 2015;385:1406-1417. [PMID: 25542620 DOI: 10.1016/s0140-6736(14)61908-5] [Cited by in Crossref: 306] [Cited by in F6Publishing: 82] [Article Influence: 43.7] [Reference Citation Analysis]
370 Yoshida K, Fukunaga K, Ikeuchi H, Kamikozuru K, Hida N, Ohda Y, Yokoyama Y, Iimuro M, Takeda N, Kato K, Kikuyama R, Nagase K, Hori K, Nakamura S, Miwa H, Matsumoto T. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: a 3-year prospective randomized open trial. Inflamm Bowel Dis. 2012;18:1617-1623. [PMID: 22081474 DOI: 10.1002/ibd.21928] [Cited by in Crossref: 100] [Cited by in F6Publishing: 83] [Article Influence: 10.0] [Reference Citation Analysis]
371 Vermeire S, van Assche G, Rutgeerts P. Review article: Altering the natural history of Crohn’s disease--evidence for and against current therapies. Aliment Pharmacol Ther. 2007;25:3-12. [PMID: 17229216 DOI: 10.1111/j.1365-2036.2006.03134.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 36] [Article Influence: 0.7] [Reference Citation Analysis]
372 Crespi M, Dulbecco P, De Ceglie A, Conio M. Strictures in Crohn's Disease: From Pathophysiology to Treatment. Dig Dis Sci 2020;65:1904-16. [PMID: 32279173 DOI: 10.1007/s10620-020-06227-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
373 Rieder F, Fiocchi C. Intestinal fibrosis in inflammatory bowel disease - Current knowledge and future perspectives. J Crohns Colitis. 2008;2:279-290. [PMID: 21172225 DOI: 10.1016/j.crohns.2008.05.009] [Cited by in Crossref: 86] [Cited by in F6Publishing: 83] [Article Influence: 6.6] [Reference Citation Analysis]
374 Magro F, Santos-Antunes J, Vilas-Boas F, Rodrigues-Pinto E, Coelho R, Ribeiro OS, Lopes S, Macedo G. Crohn's disease outcome in patients under azathioprine: a tertiary referral center experience. J Crohns Colitis 2014;8:617-25. [PMID: 24332869 DOI: 10.1016/j.crohns.2013.11.020] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
375 Panés J, López-Sanromán A, Bermejo F, García-Sánchez V, Esteve M, Torres Y, Domènech E, Piqueras M, Gomez-García M, Gutiérrez A. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn’s disease. Gastroenterology. 2013;145:766-774.e1. [PMID: 23770132 DOI: 10.1053/j.gastro.2013.06.009] [Cited by in Crossref: 171] [Cited by in F6Publishing: 131] [Article Influence: 21.4] [Reference Citation Analysis]
376 Navaratne L, Hurndall KH, Richardson DM, Stephenson R, Power N, Gillott H, Ruiz Sánchez S, Khodatars K, Chan CLH. Risk factors for symptomatic anastomotic postoperative recurrence following ileo-colic resection in Crohn's disease. Colorectal Dis 2021;23:1184-92. [PMID: 33448576 DOI: 10.1111/codi.15530] [Reference Citation Analysis]
377 Rieder F, Fiocchi C. Intestinal fibrosis in IBD--a dynamic, multifactorial process. Nat Rev Gastroenterol Hepatol. 2009;6:228-235. [PMID: 19347014 DOI: 10.1038/nrgastro.2009.31] [Cited by in Crossref: 193] [Cited by in F6Publishing: 187] [Article Influence: 16.1] [Reference Citation Analysis]
378 Armuzzi A, Felice C, Papa A, Marzo M, Pugliese D, Andrisani G, Federico F, De Vitis I, Rapaccini GL, Guidi L. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study. J Crohns Colitis. 2013;7:e623-e629. [PMID: 23810678 DOI: 10.1016/j.crohns.2013.04.020] [Cited by in Crossref: 63] [Cited by in F6Publishing: 52] [Article Influence: 7.9] [Reference Citation Analysis]
379 Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, Plevy S, Popp J, Cornillie FJ, Lukas M, Danese S, Gionchetti P, Hanauer SB, Reinisch W, Sandborn WJ, Sorrentino D, Rutgeerts P; PREVENT Study Group. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. Gastroenterology. 2016;150:1568-1578. [PMID: 26946343 DOI: 10.1053/j.gastro.2016.02.072] [Cited by in Crossref: 141] [Cited by in F6Publishing: 105] [Article Influence: 28.2] [Reference Citation Analysis]
380 Bokemeyer B. CED-Behandlung in Deutschland: Betrachtungen zur sinnvollen Vernetzung. Gastroenterologe 2007;2:447-55. [DOI: 10.1007/s11377-007-0113-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
381 Van Assche G, Herrmann KA, Louis E, Everett SM, Colombel JF, Rahier JF, Vanbeckevoort D, Meunier P, Tolan D, Ernst O. Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn’s disease. J Crohns Colitis. 2013;7:950-957. [PMID: 23411006 DOI: 10.1016/j.crohns.2013.01.011] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 8.9] [Reference Citation Analysis]
382 Panaccione R, Rutgeerts P, Sandborn WJ, Feagan B, Schreiber S, Ghosh S. Review article: treatment algorithms to maximize remission and minimize corticosteroid dependence in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2008;28:674-688. [PMID: 18532990 DOI: 10.1111/j.1365-2036.2008.03753.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 5.3] [Reference Citation Analysis]
383 Bettenworth D, Lopez R, Hindryckx P, Levesque BG, Rieder F. Heterogeneity in endoscopic treatment of Crohn’s disease-associated strictures: An international inflammatory bowel disease specialist survey. J Gastroenterol 2016;51:939-48. [DOI: 10.1007/s00535-016-1172-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
384 Latella G, Cocco A, Angelucci E, Viscido A, Bacci S, Necozione S, Caprilli R. Clinical course of Crohn’s disease first diagnosed at surgery for acute abdomen. Dig Liver Dis. 2009;41:269-276. [PMID: 18955023 DOI: 10.1016/j.dld.2008.09.010] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
385 Targownik LE, Nugent Z, Singh H, Bernstein CN. Prevalence of and Outcomes Associated with Corticosteroid Prescription in Inflammatory Bowel Disease: . Inflammatory Bowel Diseases 2014;20:622-30. [DOI: 10.1097/mib.0000000000000008] [Cited by in Crossref: 35] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
386 Etchevers MJ, Aceituno M, Sans M. Are we giving azathioprine too late? The case for early immunomodulation in inflammatory bowel disease. World J Gastroenterol. 2008;14:5512-5518. [PMID: 18810768 DOI: 10.3748/wjg.14.5512] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.4] [Reference Citation Analysis]
387 de Bruyn JR, Becker MA, Steenkamer J, Wildenberg ME, Meijer SL, Buskens CJ, Bemelman WA, Löwenberg M, Ponsioen CY, van den Brink GR, D'Haens GR. Intestinal fibrosis is associated with lack of response to Infliximab therapy in Crohn's disease. PLoS One 2018;13:e0190999. [PMID: 29364909 DOI: 10.1371/journal.pone.0190999] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
388 Stournaras E, Qian W, Pappas A, Hong YY, Shawky R, Raine T, Parkes M; UK IBD BioResource Investigators., UK IBD Bioresource Investigators. Thiopurine monotherapy is effective in ulcerative colitis but significantly less so in Crohn's disease: long-term outcomes for 11 928 patients in the UK inflammatory bowel disease bioresource. Gut 2021;70:677-86. [PMID: 33004550 DOI: 10.1136/gutjnl-2019-320185] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
389 Siegel CA, Siegel LS, Hyams JS, Kugathasan S, Markowitz J, Rosh JR, Leleiko N, Mack DR, Crandall W, Evans J. Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease. Inflamm Bowel Dis. 2011;17:30-38. [PMID: 20812335 DOI: 10.1002/ibd.21386].] [Reference Citation Analysis]
390 Yassin S, Isakov NF, Ron Y, Cohen NA, Hirsch A, Maharshak N. A watchful waiting approach for newly diagnosed Crohn's disease patients with an inflammatory phenotype. Int J Colorectal Dis 2021;36:735-43. [PMID: 33404768 DOI: 10.1007/s00384-020-03811-8] [Reference Citation Analysis]
391 Burke JP. Role of Fecal Diversion in Complex Crohn's Disease.Clin Colon Rectal Surg. 2019;32:273-279. [PMID: 31275074 DOI: 10.1055/s-0039-1683916] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
392 Ueda T, Koyama F, Nakamoto T, Obara S, Inoue T, Sasaki Y, Kuge H, Fujii H, Sho M. Endoscopic Features of Postoperative Anastomotic Lesions in Patients with Crohn's Disease Compared with Right-side Colon Cancer: Are Anastomotic Linear Superficial Ulcers Recurrent in Crohn's Disease? J Anus Rectum Colon 2021;5:158-66. [PMID: 33937556 DOI: 10.23922/jarc.2020-088] [Reference Citation Analysis]
393 Ford MM. Crohn's Disease Obstructions. Clin Colon Rectal Surg 2021;34:227-32. [PMID: 34305471 DOI: 10.1055/s-0041-1729926] [Reference Citation Analysis]
394 Banovic I, Gilibert D, Cosnes J. Perception of improved state of health and subjective quality of life in Crohn's disease patients treated with Infliximab. J Crohns Colitis 2009;3:25-31. [PMID: 21172244 DOI: 10.1016/j.crohns.2008.10.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
395 Robineau O, Enrico J, Lemaire X, Poissy J, Legout L, Senneville E, Colombel JF, Yazdanpanah Y. Herpes simplex virus meningoencephalitis in a patient with Crohn’s disease on azathioprine therapy. Am J Gastroenterol. 2010;105:240-241. [PMID: 20054331 DOI: 10.1038/ajg.2009.544] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
396 Manresa MC, Godson C, Taylor CT. Hypoxia-sensitive pathways in inflammation-driven fibrosis. Am J Physiol Regul Integr Comp Physiol 2014;307:R1369-80. [PMID: 25298511 DOI: 10.1152/ajpregu.00349.2014] [Cited by in Crossref: 28] [Cited by in F6Publishing: 24] [Article Influence: 4.0] [Reference Citation Analysis]
397 Rubin DT, Uluscu O, Sederman R. Response to biologic therapy in Crohn's disease is improved with early treatment: an analysis of health claims data. Inflamm Bowel Dis 2012;18:2225-31. [PMID: 22359399 DOI: 10.1002/ibd.22925] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 5.7] [Reference Citation Analysis]
398 Selinger CP, Andrews JM, Titman A, Norton I, Jones DB, Mcdonald C, Barr G, Selby W, Leong RW. Long-term Follow-up Reveals Low Incidence of Colorectal Cancer, but Frequent Need for Resection, Among Australian Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology 2014;12:644-50. [DOI: 10.1016/j.cgh.2013.05.017] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 6.1] [Reference Citation Analysis]
399 Travis S. Advances in therapeutic approaches to ulcerative colitis and Crohn's disease. Curr Gastroenterol Rep. 2005;7:475-484. [PMID: 16313878 DOI: 10.1007/s11894-005-0079-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
400 Zhao S, Dejanovic D, Yao P, Bhilocha S, Sadler T, Schirbel A, West G, Doyon G, Lopez R, Mao R, Kurada S, El Ouali S, Grassl G, Fox PL, Cruise M, Worthley DL, de la Motte C, Fiocchi C, Rieder F. Selective deletion of MyD88 signaling in α-SMA positive cells ameliorates experimental intestinal fibrosis via post-transcriptional regulation. Mucosal Immunol 2020;13:665-78. [PMID: 32020030 DOI: 10.1038/s41385-020-0259-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
401 Rieder F, Reinisch W. Thiopurines and the Natural Course of Crohn's Disease: Did We Finally Find the Right Therapeutic Target? American Journal of Gastroenterology 2014;109:1037-40. [DOI: 10.1038/ajg.2014.162] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
402 Lakatos PL, Golovics PA, David G, Pandur T, Erdelyi Z, Horvath A, Mester G, Balogh M, Szipocs I, Molnar C, Komaromi E, Veres G, Lovasz BD, Szathmari M, Kiss LS, Lakatos L. Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am J Gastroenterol. 2012;107:579-588. [PMID: 22233693 DOI: 10.1038/ajg.2011.448] [Cited by in Crossref: 157] [Cited by in F6Publishing: 143] [Article Influence: 17.4] [Reference Citation Analysis]
403 Zhu Y, Xu H, Liu W, Qi W, Yang X, Ye L, Cao Q, Zhou W. Glasgow prognostic score is a practical predictive index for postoperative intra-abdominal septic complications after bowel resection in Crohn's disease patients. Int J Colorectal Dis 2018;33:947-53. [PMID: 29687374 DOI: 10.1007/s00384-018-3035-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
404 Makharia GK. Quality of care in Crohn's disease. World J Gastrointest Pathophysiol 2014;5:462-6. [PMID: 25400990 DOI: 10.4291/wjgp.v5.i4.462] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
405 Iesalnieks I, Kilger A, Glass H, Müller-Wille R, Klebl F, Ott C, Strauch U, Piso P, Schlitt HJ, Agha A. Intraabdominal septic complications following bowel resection for Crohn’s disease: detrimental influence on long-term outcome. Int J Colorectal Dis. 2008;23:1167-1174. [PMID: 18690466 DOI: 10.1007/s00384-008-0534-9] [Cited by in Crossref: 67] [Cited by in F6Publishing: 57] [Article Influence: 5.2] [Reference Citation Analysis]
406 Rodríguez-lago I, Gisbert JP. The Role of Immunomodulators and Biologics in the Medical Management of Stricturing Crohn’s Disease. Journal of Crohn's and Colitis 2020;14:557-66. [DOI: 10.1093/ecco-jcc/jjz158] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
407 Sandborn WJ. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology. 2008;135:1442-1447. [PMID: 18848556 DOI: 10.1053/j.gastro.2008.09.053] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 5.8] [Reference Citation Analysis]
408 Singh H, Nugent Z, Demers AA, Bernstein CN. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology. 2011;141:1612-1620. [PMID: 21806945 DOI: 10.1053/j.gastro.2011.07.039] [Cited by in Crossref: 97] [Cited by in F6Publishing: 87] [Article Influence: 9.7] [Reference Citation Analysis]
409 Coskun M, Steenholdt C, de Boer NK, Nielsen OH. Pharmacology and Optimization of Thiopurines and Methotrexate in Inflammatory Bowel Disease. Clin Pharmacokinet. 2016;55:257-274. [PMID: 26255287 DOI: 10.1007/s40262-015-0316-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 5.6] [Reference Citation Analysis]